+

WO1997040042A1 - Heterocyclic compounds - Google Patents

Heterocyclic compounds Download PDF

Info

Publication number
WO1997040042A1
WO1997040042A1 PCT/US1997/006679 US9706679W WO9740042A1 WO 1997040042 A1 WO1997040042 A1 WO 1997040042A1 US 9706679 W US9706679 W US 9706679W WO 9740042 A1 WO9740042 A1 WO 9740042A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
yloxy
heptane
group
azabicyclo
Prior art date
Application number
PCT/US1997/006679
Other languages
French (fr)
Inventor
Leander Merritt
Lone Jeppson
John S. Ward
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Priority to JP9538263A priority Critical patent/JP2000509044A/en
Priority to US09/171,793 priority patent/US6069159A/en
Priority to AU26794/97A priority patent/AU2679497A/en
Priority to EP97918771A priority patent/EP0900217A4/en
Publication of WO1997040042A1 publication Critical patent/WO1997040042A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to therapeutically active heterocyclic compounds having surprising potency and favorable side effect profile.
  • the novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals.
  • Alzheimer's disease Due to the generally improved health situation in the western world, elderly-related diseases are much more common now than in the past and are likely to be even more common in the future.
  • One of the elderly-related symptoms is a reduction of the cognitive functions. This symptom is especially pronounced in the pathophysiological disease known as Alzheimer's disease.
  • This disease is combined with, and also most likely caused by, an up to 90% degeneration of the muscarinic cholinergic neurons in nucleus basalis, which is part of substantia innominata. These neurons project to the prefrontal cortex and hippocampus and have a general stimulatory effect on the cognitive functions of the forebrain as well as of hippocampus, namely learning, association, consolidation, and recognition.
  • muscarinic cholinergic agonists are useful in the treatment of
  • Alzheimer's disease in halting its progression, and in improving the cognitive functions of elderly people.
  • muscarinic cholinergic receptor active compounds are also useful analgesic agents and therefore are useful in the treatment of severely painful conditions. Furthermore, muscarinic cholinergic receptor active compounds are useful in the treatment of glaucoma, psychosis, anxiety, mania, bipolar disorder, schizophrenia or schizophreniform conditions, depression, sleeping disorders, epilepsy, cerebral ischemia, and gastrointestinal motility disorders.
  • muscarinic cholinergic receptor active compounds are associated with side effects attributed to undesired modulation of the muscarinic cholinergic receptors, for example, such undesired modulation may cause excessive salivation and gastrointestinal upset.
  • the most desired muscarinic cholinergic compounds shall have high potency and at the same time a favorable side effect profile, including a low incidence of excessive salivation.
  • the presently claimed compounds are surprisingly potent and most preferredly provide a favorable side effect profile.
  • Studies of compounds claimed herein suggest that certain compounds will be highly desired muscarinic receptor active compounds which can be particularly useful pharmaceutically active compounds.
  • This invention provides compounds of the formula I :
  • W is S or 0
  • R 8 is selected from the group consisting of hydrogen and C 1 -C 4 alkyl;
  • R 10 ' is C 2 -C 5 alkynyl;
  • R 11 ' is aryl or 5 to 6 membered heterocyclic ring each of which is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, C ⁇ - 4 -alkyl, C ⁇ - 4 -alkoxy, -OCF 3 , -CF 3 , -CONH 2 , -CSNH 2 ; -OH, -COR 6 ', CH 2 -OH, and -NH 2 ;
  • G is selected from one of the following azacyclic or azabicyclic ring systems:
  • G is optionally substituted C 3 -C 8 cycloalkyl wherein the cycloalkyl substituents are selected from R 1 and R 2 ; or optionally substituted Ci- ⁇ -alkyl wherein the substitution is -NR 6 R 7;
  • R 6 and R 7 independently are selected from the group consisting of hydrogen and C ⁇ - 6 -alkyl; or R 6 and R 7 together with the nitrogen atom optionally form a 4- to 6-member ring;
  • R 1 and R 2 independently are selected from the group consisting of hydrogen, C ⁇ - 15 -alkyl, C 2 - 5 ⁇ alkenyl, C2-5- alkynyl, C ⁇ - 10 -alkoxy, and C ⁇ -5-alkyl substituted with one or more independently selected from the group consisting of -OH, -COR 6 ', CH 2 -OH, halogen, -NH2, carboxy,
  • R 9 and R 9' are each independently selected from the group consisting of hydrogen, halogen, C ⁇ - 4 -alkoxy, C ⁇ - 4 -alkyl, -CN, -OCF3, -CONH 2 and -CSNH 2 ;
  • R 6 ' is hydrogen, C ⁇ - 6 -alkyl
  • R 3 is selected from the group consisting of hydrogen, Ci-
  • Preferred compounds are those wherein R 10 ' is propargyl.
  • the present invention further provides a formulation comprising a compound of Formula I and one or more carriers or diluents therefor.
  • the present invention provides a method for treating a condition which is mediated by a muscarinic receptor comprising administering an effective amount of a compound of Formula I to a mammal in need of such treatment.
  • the invention extends to each of the stereoisomeric forms of the compounds of the present invention as well as the pure diastereomeric, pure enatiomeric, and racemic forms of the compounds of this invention.
  • treating includes prophylaxis of a physical and/or mental condition or amelioration or elimination of the developed physical and/or mental condition once it has been established or alleviation of the characteristic symptoms of such condition.
  • a condition which is mediated by a muscarinic receptor shall refer to a condition which can be treated by administering a compound which acts as a muscarinic receptor antagonist, agonist, or mixed agonist at a muscarinic receptor.
  • Such conditions shall include, but are not limited to, Alzheimer's disease, severely painful conditions, glaucoma, psychosis, anxiety, mania, bipolar disorder, schizophrenia or schizophreniform conditions, depression, sleeping disorders, epilepsy, cerebral ischemia, and gastrointestinal motility disorders.
  • halogen means Cl
  • halogens include Cl, Br, and I.
  • a particularly preferred halogen is Cl.
  • aryl has the meaning commonly attributed to the term by the artisan.
  • the term means molecules whose ring structure is characteristic of benzene, naphthalene, phenanthrene, anthracene, and the like.
  • an aryl radical could be, but is not limited to, phenyl, benzyl, naphthylene, and the like.
  • alkoxide metal means a metal suitable for alkoxide formation.
  • alkoxide metals include, but are not limited to, Li + , K + , Na + , Cs + , and Ca ++ .
  • Especially preferred alkoxide metals include Li + , K + , and Na + .
  • the phrase "5 or 6 member heterocyclic group” means a group containing from one to four N, 0 or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with C ⁇ - 6 -alkyl, -CF 3 , phenyl, benzyl or thienyl, or a carbon atom in the heterocyclic group together with an oxygen atom form a carbonyl group, or which heterocyclic group is optionally fused with a phenyl group.
  • the phrase “5 or 6 membered heterocyclic group” includes, but is not limited to, 5-membered heterocycles having one hetero atom (e.g.
  • 5-membered heterocycles having two heteroatoms in 1,2 or 1,3 positions e.g. oxazoles, pyrazoles, imidazoles, thiazoles, purines
  • 5-membered heterocycles having three heteroatoms e.g. triazoles, thiadiazoles
  • 5-membered heterocycles having 3- heteroatoms 6-membered heterocycles with one heteroatom (e.g. pyridine, quinoline, isoquinoline, phenanthrine, 5, 6-cycloheptenopyridine) ; 6-membered heterocycles with two heteroatoms (e.g.
  • Particularly preferred are thiophenes, pyridines, and furans.
  • C n '-C 4 alkyl wherein n'can be 1 or 2, as used herein, represent a branched or linear alkyl group having from one to 4 carbon atoms.
  • Typical C 1 -C 4 alkyl groups include, but are not limited to, methyl, ethyl, n- propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl and the like.
  • C 1 -C 4 alkoxy refers to a carboxy group such as, but not limited to, methoxy, ethoxy, propoxy, butoxy, and the like.
  • the alkoxy substituent is attatched to the parent molecule through the oxygen atom of the alkoxy group.
  • Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically-acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are known to the skilled artisan.
  • the compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
  • R is selected from the group consisting of hydrogen, amino, halogen, NHR 6 , NR 6 R 7 , R 4 , -OR 4 , -SR 4 , -SOR 4 , -S0 2 R 4 , C 3 - ⁇ rj-cycloalkyl, C 4 _i 2 ⁇ (cycloalkylalkyl) , -Z-C 3 - 10 - cycloalkyl and -Z-C 4 - 12 - (cycloalkylalkyl) ;
  • R 4 is selected from the group consisting of C ⁇ - 15 -alkyl, C 2 -I5 ⁇ alkenyl and C2-I5 ⁇ alkynyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen (s), -CF 3 , -
  • phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, C 1 - 4 - alkyl, C ⁇ - 4 -alkoxy, -OCF 3 , -CF 3 , -CONH 2 and -CSNH 2 ; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, C ⁇ - 4 - alkyl, C ⁇ - 4 -alkoxy, -OCF3, -CF3, -CONH 2 and -CSNH 2 ; or R is selected from the group consisting of -OR 5 Y, -SR 5 Y, 0R 5 -Z-Y, -SR 5 ZY, -0-R 5 -Z-R 4 and -S-R 5 -Z-R 4 ' "
  • Z is oxygen or sulphur
  • R 5 is C ⁇ - 15 -alkyl, C 2 -i 5 -alkenyl, and C2-i 5 ⁇ alkynyl;
  • Y is a 5 or 6 membered heterocyclic group
  • G is selected from one of the following azacyclic or azabicyclic ring systems:
  • G is optionally substituted C 3 -C 8 cycloalkyl wherein the cycloalkyl substituents are selected from R 1 and R 2 ; or optionally substituted Ci-e-alkyl wherein the substitution is -NR 6 R 7 ' *
  • R 6 and R 7 independently are selected from the group consisting of hydrogen and C ⁇ - 6 _ alkyl; or R 6 and R 7 together with the nitrogen atom optionally form a 4- to 6-member ring;
  • R 1 and R 2 independently are selected from the group consisting of hydrogen, C ⁇ -15-alkyl, C2-5 _ alkenyl, C2-5- alkynyl, C ⁇ - ⁇ rj-alkoxy, and C ⁇ -5-alkyl substituted with one or more independently selected from the group consisting of -OH, -COR 6 ', CH 2 -0H, halogen, -NH2, carboxy,
  • R 9 and R 9' are each independently selected from the group consisting of hydrogen, halogen, C ⁇ -4-alkoxy, C ⁇ -4-alkyl,
  • R 6 ' is hydrogen, C ⁇ -6-alkyl
  • R 3 is selected from the group consisting of hydrogen, Ci-
  • the compounds of this invention can be prepared using the chemical processes illustrated in Scheme I' and Scheme I.
  • the starting materials for the illustrated process are commercially available or may be prepared using methods known to the skilled artisan.
  • P may be hal or SO 2 R 9 ;
  • Q may be N, O or S;
  • R 24 is selected from the group consisting of hydrogen, R 4 , R 5 , R 6 , and R 7;
  • R 25 is selected from the group consisting of SOR 4 and SO 2 R 4 ; all other meanings are as defined supra .
  • Hal, W, r, and G are as defined supra .
  • R 22 and R 23 are independently selected from the group consisting of hydrogen, R 6 and R 7 .
  • R 8 , Si, R 10 ,R 1:L , R 12 , R 13 , R 14 , R 15 ', R 15 and R 16 are as defined supra .
  • R 8 N[ (R 10 R 11 R 12 Si) (R 13 R 14 R 15 'Si) may be, but is not limited to lithium bis (tri-2-propylsilyl)amide, sodium bis (trimethylsilyl)amide, potassium bis (trimethylsilyl)amide, lithium bis(tri-2- propylsilyl)amide, sodium bis (ethyldimethylsilyl)amide, potassium bis (1-propylethylmethylsilyl)amide, lithium bis (tri-phenylsilyl) amide, sodium bis(tri- phenylmethylsilyl) amide, potassium bis (2-butyl-2- propylmethylsilyl) amide, lithium (tri-2-propylsilyl) (2- butyldiethylsilyl) amide, sodium
  • R 15 and R 16 are each hydrogen when the process of Scheme III is used for preparing a compound of 11 from a compound of 10.
  • the intermediate 10 may be nitrosated using standard nitrosating procedures.
  • a preferred nitrosating agent is isoamyl nitrite; however, other known nitrosating agents are appropriate.
  • the term "Cu(Br,I)" refers to copper (I) bromide, copper (II) bromide, or copper (I) iodide. The artisan will recognize that the copper (I) bromide, copper (II) bromide, or copper (I) iodide reagent shall determine the substitution on the product of the process illustrated in Scheme III.
  • Certain compounds of this invention may more preferably be prepared by a process using a hydroxyalkylamine (G-OH) wherein G has the meaning defined supra , in the presence of a phosphorus (III) compound and a diester of azodicarboxylate to give the 1,2,5- thiadiazoyloxyalkylamine as illustrated by Scheme V and V ,
  • the G group is 2-aza-bicyclo [2.2.1]heptane.
  • the R' is selected from the group consisting of -OR 4 and - SR 4
  • R 4 is selected from the group consisting of C ⁇ - 15 -alkyl, C2-i 5 -alkenyl, C2-i5 _ alkynyl and 5-membered heterocycle, each of which is optionally substituted with one or more independently selected from the group consisting of halogen(s), -CF 3 , -CN, Y, phenyl and phenoxy wherein phenyl or phenoxy is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, C ⁇ _ 4 -alkyl, C ⁇ - 4 -alkoxy, -OCF 3 , or -CF 3 ; or
  • R' is phenyl or benzyloxycarbonyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, C 1 - 4 - alkyl, C ⁇ - 4 -alkoxy, -OCF 3 , and -CF 3 ; or
  • R' selected from the group consisting of -OR 5 Y, -SR 5 Y,
  • R 5 is selected from the group consisting of C ⁇ - 15 -alkyl
  • Y is a 5-membered heterocyclic group
  • R 1 ' is selected from the group consisting of phenyl, C ⁇ _ 15 -alkyl, C2-5-alkenyl, C2-5 ⁇ alkynyl and (NR 2 ') 3 ;
  • R 2 ' and R 3 ' are independently selected from the group consisting of hydrogen, C ⁇ - 15 -alkyl, C2- 5 ⁇ alkenyl, C2- 5 - alkynyl, and C ⁇ -5-alkyl substituted with one or more selected from the group consisting of halogen and phenyl;
  • W is oxygen or sulphur;
  • R 6 , and R 7 independently are C ⁇ - 6 -alkyl; or R 6 and R 7 together with the nitrogen atom optionally form a 4- to 6-member ring;
  • R 1 and R 2 independently are selected from the group consisting of hydrogen, C ⁇ - 15 -alkyl, C 2 - 5 -alkenyl, C2-5- alkynyl, C ⁇ - 10 -alkoxy, and C ⁇ - 5 -alkyl substituted with one or more independently selected from the group consisting of -OH, -COR 6 ', CH 2 -0H, halogen, -NH2, carboxy,
  • R 9 and R 9' are each independently selected from the group consisting of hydrogen, halogen, C ⁇ - 4 -alkoxy, C ⁇ - 4 -alkyl,
  • R 6 ' is hydrogen or C 1 -C 3 alkyl
  • R 3 is selected from the group consisting of C ⁇ - 5 -alkyl
  • C 2 - 5 ⁇ alkenyl and C 2 - 5 _ alkynyl n is O, 1 or 2; m is 0, 1 or 2; p is O, 1 or 2; q is 1 or 2; r is 0, 1 or 2; is a single or double bond.
  • R 1 ' groups include phenyl, C ⁇ - 15 -alkyl, and (NR 2 ') 3 .
  • the process of Scheme IV is particularly advantageous because the process provides a method for inverting the stereochemistry at the carbon bearing the hydroxyl group in G.
  • G(CH2) r w is 2-Aza- bicyclo[2.2.1]heptane and R 6 ' is selected from the group consisting of R 7 , -OR 7 , -SR 7 , -SOR 7 , -S0 2 R 7 , C3- 10 - cycloalkyl, C 4 - 12 - (cycloalkylalkyl) , -Z-C 3 - ⁇ o-cycloalkyl and -Z-C 4 - 12 - (cycloalkylalkyl) ;
  • R 7 is C ⁇ - 15 -alkyl, C2-i5 ⁇ alkenyl, C2-i5 _ alkynyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen (s), -CF 3 , -CN, Y, phenyl and phenoxy; wherein phenyl or phenoxy is optionally substituted with one or more selected from the group consisting of halogen, -CN, C 1 - 4 - alkyl, C ⁇ - 4 -alkoxy, -OCF 3 , and -CF 3 ; provided that at least one alkyl atom of R 6 ' is substituted with a hydroxyl group or R 6 'is a substituent selected from the group consisting of -OR 8 Y, -SR 8 Y, OR 8 -Z-Y, -SR 8 ZY, -0- R 8 -Z-R 7 and -S-R 8 -Z-R 7 wherein each -0R
  • Y is a 5 or 6 membered heterocyclic group; Z is oxygen or sulphur; R 8 is C ⁇ - 15 -alkyl, C2-i5 ⁇ alkenyl, C2-i5 ⁇ alkynyl; aryl and heteroaryl is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, C ⁇ - 4 -alkyl, C ⁇ - 4 -alkoxy, C ⁇ - 4 -alkylthio, C 1 - 4 - alkylsulfone, C ⁇ -4-alkylsulfoxide, -OCF 3 , NO 2 , N(R 7 ) 2 , and - CF 3 ; heteroaryl group is a 5 or 6 membered heterocycle containing one to four N, 0, or S atoms or a combination thereof.
  • Scheme VIII Another process of this invention, illustrated by Scheme VIII, is the synthesis of 3-hydroxy-4-alkylthio- 1, 2, 5-thiadiazoles by treating 3-halo-4-alkylthio-l, 2, 5- thiadiazoles with aqueous alkaline metal hydroxides in the presence or absence of a dipolar aprotic solvent.
  • Hal has the meanings defined supra
  • M is an alkali metal
  • W is 0 or S.
  • R R is hydrogen, R 4 , C 3 _ ⁇ o-cycloalkyl, C 4 - 12 - (cycloalkylalkyl) , R 4 -Z-C 3 - ⁇ 0 -cycloalkyl and R 4 -Z-C 4 _ 12 - (cycloalkylalkyl) ;
  • W is oxygen or sulfur;
  • R 4 is selected from the group consisting of C ⁇ _i 5 -alkyl, C2-15 ⁇ alkenyl, and C2-i5-alkynyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen(s), -CF 3 , Y, phenyl and phenoxy; wherein phenyl or phenoxy is optionally substituted with one or more selected from the group consisting of halogen, C ⁇ - 4 -alkyl, C ⁇ - 4 -alkoxy, and
  • R R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with one or more selected from the group consisting of halogen, C ⁇ - 4 -alkyl, C ⁇ - 4 -alkoxy, and
  • R R is R 4 -OR 5 Y, R 4 -SR 5 Y, R 4 -OR 5 -Z-Y, R 4 -SR 5 ZY, R 4 -0-R 5 -Z-R 4 or R 4 -S-R 5 -Z-; Z is oxygen or sulphur;
  • R 5 is selected from the group consisting of C ⁇ - 15 -alkyl, C2-i5 _ alkenyl, and C2-i5-alkynyl;
  • Y is a 5 or 6 membered heterocyclic group
  • R 6 , and R 7 independently are hydrogen, C ⁇ - 6 _ alkyl, or R 6 and R 7 together with the nitrogen atom optionally form a 4- to 6-member ring;
  • R 1 and R 2 independently are hydrogen, C]__i 5 -alkyl, C2-5- alkenyl, C2-5 ⁇ alkynyl, C ⁇ - 10 -alkoxy, C ⁇ -5-alkyl substituted with -OH, -COR 6 ', CH 2 -OH, halogen, -NH2, carboxy, or phenyl;
  • R 6 ' is hydrogen or C 1 -C 3 alkyl
  • W is 0 or S;
  • Hal is selected from Cl, Br, F, I, and if W is O then Hal may be SO 2 R 4 ' ;
  • R 4 ' is C 1 -C 3 alkyl or phenyl.
  • the compounds (11) are useful intermediates for the preparation of 1, 2, 5-thiadiazole compounds.
  • the artisan will recognize that the intermediates 11 are useful for preparing 1, 2, 5-thiadiazole compounds as illustrated by the processes of Schemes I, II, and III.
  • the protecting group may be removed using standard methods known to the skilled artisan.
  • An especially preferred protecting group is carbamate.
  • One particularly useful reference concerning protecting groups is Greene, Protecting Groups in Organic Synthesis, (John Wiley & Sons, New York, 1981) .
  • the concentration of the reactants is not critical. The art worker can alter the concentration of the reactants to achieve the desired rate of reaction and product yield.
  • the length of time for carrying out the processes described are not critical. As is always the case in chemistry, the rate of the reaction depends on a variety of factors, such as the temperature and the exact compound which is to be prepared.
  • the course of the reaction may be followed using methods such as thin layer chromatography (TLC) , high performance liquid chromatography (HPLC) , gas chromatography (GC) and nuclear magnetic resonance spectroscopy (NMR) to detect the degree of completion of the reaction.
  • TLC thin layer chromatography
  • HPLC high performance liquid chromatography
  • GC gas chromatography
  • NMR nuclear magnetic resonance spectroscopy
  • the operator may obtain maximum yields using the process by extending the reaction time. Alternatively, the operator may wish to obtain maximum throughput by cutting off the reaction at the point at which it reaches an economical degree of completion.
  • the product of a step in the following process is an oil
  • it may be isolated by standard methods. Such methods include distillation, flash chromatography, HPLC and the like.
  • malfunctioning of the muscarinic cholinergic system shall have the meaning accepted by the skilled artisan.
  • the term shall refer to, but is not in any way limited to, conditions such as glaucoma, psychosis, schizophrenia or schizophreniform conditions, depression, sleeping disorders, epilepsy, and gastrointestinal motility disorders. Other such conditions include Alzheimer's Disease and incontinence.
  • the pharmacological properties of the compounds of the invention can be illustrated by determining their capability to inhibit the specific binding of 3 H- Oxotremorine-M ( 3 H-Oxo) .
  • the Character of Muscarinic Receptors in Different Regions of the Rat Brain Proc. Roy. Soc. London (Series B) 207,1.
  • the inhibitory effects of compounds on 3 H-oxo binding reflects the affinity for muscarinic acetylcholine receptors.
  • Fresh cortex (0.1-1 g) from male Wistar rats (150-250 g) is homogenized for 5-10 seconds in 10 mL 20 nM Hepes pH: 7.4, with an Ultra-Turrax homogenizer. The homogenizer is rinsed with 10 mL of buffer and the combined suspension centrifuged for 15 min. at 40,000 x g. The pellet is washed three times with buffer. In each step the pellet is homogenized as before in 2 x 10 mL of buffer and centrifuged for 10 min. at 40, 000 x g.
  • the final pellet is homogenized in 20 mM Hepes pH: 7.4 (100 mL per g of original tissue) and used for binding assay. Aliquots of 0.5 mL is added 25 ⁇ L of test solution and 25 ⁇ L of 3 H-Oxotremorine (1.0 nM, final concentration) mixed and incubated for 30 min. at 25°C. Non-specific binding is determined in triplicate using arecoline (1 ⁇ g/mL, final concentration) as the test substance. After incubation samples are added 5 mL of ice-cold buffer and poured directly onto Whatman GF/C glass fiber filters under suction and immediately washed 2 times with 5 mL of ice-cold buffer. The amount of radioactivity on the filters are determined by conventional liquid scintillation counting. Specific binding is total binding minus non specific binding.
  • Test substances are dissolved in 10 mL water
  • IC50 (applied test substance concentration) x(C x /C 0 - C x )nM where C 0 is specific binding in control assays and C x is the specific binding in the test assay. (The calculations assume normal mass-action kinetics) .
  • the pharmacological properties of the compounds of the invention can also be illustrated by determining their capability to inhibit 3 HPRZ (pirenzepine, [N-methyl- 3 H] ) binding to rat cerebral cortex membranes.
  • Pirenzepine binds selectively to subtype of muscarinic receptors. Historically the type is named the Mi-site, whereas pirenzepine sensitive site would be more appropriate.
  • M ⁇ -sites pirenzepine also interact with M 2 ⁇ sites.
  • Fresh cortex (0.1-1 9) from male Wistar rats (150-200 g) is homogenized for 5-10 s in 10 mL 20 mM Hepes pH: 7.4, with an Ultra-Turrax homogenizer. The homogenizer is rinsed with 2 x 10 mL of buffer and the combined suspension centrifuged for 15 min. at 40,000 x g. The pellet is washed three times with buffer. In each step the pellet is homogenized as before in 3 x 10 mL of buffer and centrifuged for 10 min. at 40,000 x g.
  • the final pellet is homogenized in 20 mM Hepes pH: 7.4 (100 mL per g of original tissue) and used for binding assay. Aliquots of 0.5 mL is added 20 ⁇ l of test solution and 25 ⁇ L of 3 HPRZ (1.0 nM, final cone), mixed and incubated for 60 min. at 20°C. Non-specific binding is determined in triplicate using atropine (1 , ⁇ g/mL, final cone.) as the test substance. After incubation samples are added 5 mL of ice-cold buffer and poured directly onto Whatman GF/C glass fiber filters under suction and immediately washed 2 times with 5 mL of ice- cold buffer. The amount of radioactivity on the filters are determined by conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.
  • Test substances are dissolved in 10 mL water, at a concentration of 0.22 mg/mL. 25-75% inhibition of specific binding must be obtained before calculation of IC50.
  • the test value will be given as IC 50 (the concentration (nM) of the test substance which inhibits the specific binding of 3 HPRZ by 50%) .
  • IC 50 (applied test substance concentration) x (C x /C 0 _ C x )nM where C 0 is specific binding in control assays and C x is the specific binding in the test assay. (The calculations assume normal mass-action kinetics) .
  • pharmacological activity and tendency to produce salivation can be determined or verified using the following methods:
  • A9-L-ml cells were cultured to confluence in 75 mL flasks containing Dubecco's modified essential media. Cells were prelabeled with 1 ⁇ Ci/mL of myo[2-3H] inositol (Amersham Ine, 16.3 Ci/mmol) for 48 h prior to assay. On the day of assay, cells were detached using a 30 s exposure to 0.25% trypsin in 1 mM EDTA.
  • the cells were collected by centrifugation (300xg for 5 min) and resuspended in oxygenated HEPES buffer containing 10 mM LiCl, 142 mM NaCl, 5.6 mM KCl, 2.2 mM CaCl2/ 1 mM MgCl2, 3.6 mM NaHC ⁇ 3, 5.6 mM D-glucose, and 30 mM sodium HEPES at pH 7.4.
  • Cells were incubated at 37 C for 45 miru in the presence of varying concentrations of drug.
  • the reaction was terminated by the addition of 3 mL of ice cold 10 mM LiCl, sonicated, and centrifugated at 20,000xg.
  • the supernatent was decanted over a Accell QMA anion exchange SEP-PAK cartridge in the formate form (Waters
  • [3H]PI was eluted directly into scintillation vials for counting with 4 mL of 0.1 ammonium formate/0.01 mM formic acid/5 mM sodium borate. Data is expressed as the percent of total [3H]PI stimulated in the presence of 1 mM carbachol.
  • Half-maximal values (EC50) were determined from the mean of seven point curves using a four parameter logistic model.
  • MED minimum effective dose
  • the compounds of the invention are effective over a wide dosage range.
  • dosages from about 0.05 to about 100 mg, preferably from about 0.1 to about 100 mg, per day may be used.
  • a most preferable dosage is about 0.1 mg to about 70 mg per day.
  • a dosage of from about 20 to about 70 mg per day and when the condition is under control to reduce the dosage as low as from about 0.1 to about 10 mg per day The exact dosage will depend upon the mode of administration, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or prescribing caregiver in charge.
  • the route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, depot, subcutaneous, intravenous, intramuscular or intranasal, the oral route being preferred.
  • oral or parenteral e.g. rectal, transdermal, depot, subcutaneous, intravenous, intramuscular or intranasal, the oral route being preferred.
  • compositions include a compound of formula I or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
  • a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
  • the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container.
  • the carrier When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound.
  • the active compound can be adsorbed on a granular solid container for example in a sachet.
  • suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone.
  • the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents.
  • the formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
  • the pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.
  • injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
  • Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
  • Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch.
  • a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
  • the compounds are dispensed in unit form comprising from about 0.1 to about 100 mg in a pharmaceutically acceptable carrier per unit dosage.
  • the compounds of this invention may be suitable for administration to an animal.
  • animals include both domestic animals, for example livestock, laboratory animals, and household pets, and non-domestic animals such as wildlife. More preferredly, the animal is a vertebrate.
  • a compound of this invention shall be administered to a mammal. It is especially preferred that the animal is a domestic mammal or a human. The most preferred mammal is a human.
  • a compound of this invention may be administered as a feed additive.
  • Formulation 1 A typical tablet, appropriate for use in this method, may be prepared using conventional techniques and may contain:
  • Hard gelatin capsules are prepared using the following ingredients:
  • a compound of this invention 0.1 mg 0.05 starch dried 200 mg 95.2 magnesium stearate 10 mg 4.8 210.1 mg 100
  • Formulation 3 Suspensions each containing 1 mg of medicament per 5 mL dose are as follows:
  • the medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste.
  • the benzoic acid solution, flavor and color is diluted with some of the water and added to the paste with stirring.
  • the intermediates and processes of the present invention are useful for preparing compounds having beneficial muscarinic receptor activity.
  • the compounds of the present invention have such useful muscarinic receptor activity.
  • Certain compounds and conditions within the scope of this invention are preferred.
  • the following conditions, invention embodiments, and compound characteristics listed in tabular form may be independently combined to produce a variety of preferred compounds and process conditions.
  • the following list of embodiments of this invention is not intended to limit the scope of this invention in any way.
  • R 9 is chloro and R 8 is hydrogen
  • R 9 is chloro and in the para position
  • R 8 is ethyl or isopropyl
  • R 9 is methoxy
  • R is selected from the group consisting of:
  • Endo-3- (3- [3-methyl-2-butenyl-l-oxy] -1, 2, 5-thiadiazol-4- yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 3-methyl-2-buten-l- ol. Yield: 55%. M.p. 112-115 C.
  • Compound 7. Endo-3- (3- [2-cyclopropylethyl-l-oxy] -1,2, 5-thiadiazol-4- yloxy) -1-azabicyclo [2.2.
  • Endo-3- (3- [3-methyl-2-butenyl-l-oxy] -1, 2, 5-thiadiazol-4- yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. l]heptane, oxalate and 3-methyl-2-buten-l- ol. Yield: 55%. M.p. 112-115_C.
  • Compound 7. Endo-3- (3- [2-cyclopropylethyl-l-oxy] -1,2, 5-thiadiazol-4- yloxy) -1-azabicyclo[2.2.
  • Endo-3- (3- (2-pyridyl) -2-propyn-l-yloxy) -1,2,5- thiadiazol-4-yloxy) -1-azabicyclo[2.2.1]heptane, dioxalate from endo-3- (3-propylsulfonyl-l, 2, 5- thiadiazo1-4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate and (2-pyridyl) -2-propyn-l-ol . M.p. 158-160_C. Compound 28.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides heterocyclic compounds which are useful for modulating a muscarinic receptor.

Description

HETEROCYCLIC COMPOUNDS
The present invention relates to therapeutically active heterocyclic compounds having surprising potency and favorable side effect profile. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals.
Due to the generally improved health situation in the western world, elderly-related diseases are much more common now than in the past and are likely to be even more common in the future. One of the elderly-related symptoms is a reduction of the cognitive functions. This symptom is especially pronounced in the pathophysiological disease known as Alzheimer's disease. This disease is combined with, and also most likely caused by, an up to 90% degeneration of the muscarinic cholinergic neurons in nucleus basalis, which is part of substantia innominata. These neurons project to the prefrontal cortex and hippocampus and have a general stimulatory effect on the cognitive functions of the forebrain as well as of hippocampus, namely learning, association, consolidation, and recognition.
It is a characteristic of Alzheimer's disease that although the cholinergic neurons degenerate, the postsynaptic muscarinic receptors in the forebrain and hippocampus still exist. Therefore, muscarinic cholinergic agonists are useful in the treatment of
Alzheimer's disease, in halting its progression, and in improving the cognitive functions of elderly people.
Compounds active at a muscarinic cholinergic receptor are also useful analgesic agents and therefore are useful in the treatment of severely painful conditions. Furthermore, muscarinic cholinergic receptor active compounds are useful in the treatment of glaucoma, psychosis, anxiety, mania, bipolar disorder, schizophrenia or schizophreniform conditions, depression, sleeping disorders, epilepsy, cerebral ischemia, and gastrointestinal motility disorders.
Therefore, new compounds having muscarinic cholinergic activity are desired. Some muscarinic cholinergic receptor active compounds are associated with side effects attributed to undesired modulation of the muscarinic cholinergic receptors, for example, such undesired modulation may cause excessive salivation and gastrointestinal upset. Thus, the most desired muscarinic cholinergic compounds shall have high potency and at the same time a favorable side effect profile, including a low incidence of excessive salivation.
The presently claimed compounds are surprisingly potent and most preferredly provide a favorable side effect profile. Studies of compounds claimed herein suggest that certain compounds will be highly desired muscarinic receptor active compounds which can be particularly useful pharmaceutically active compounds.
This invention provides compounds of the formula I :
Figure imgf000004_0001
W is S or 0;
R8 is selected from the group consisting of hydrogen and C1-C4 alkyl; R10' is C2-C5 alkynyl; R11' is aryl or 5 to 6 membered heterocyclic ring each of which is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, Cι-4-alkyl, Cι-4-alkoxy, -OCF3, -CF3, -CONH2, -CSNH2; -OH, -COR6', CH2-OH, and -NH2; G is selected from one of the following azacyclic or azabicyclic ring systems:
Figure imgf000005_0001
or G is optionally substituted C3-C8 cycloalkyl wherein the cycloalkyl substituents are selected from R1 and R2; or optionally substituted Ci-β-alkyl wherein the substitution is -NR6R7;
R6 and R7 independently are selected from the group consisting of hydrogen and Cχ-6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 independently are selected from the group consisting of hydrogen, Cι-15-alkyl, C2-5~alkenyl, C2-5- alkynyl, Cι-10-alkoxy, and Cι-5-alkyl substituted with one or more independently selected from the group consisting of -OH, -COR6', CH2-OH, halogen, -NH2, carboxy,
Figure imgf000006_0001
and phenyl;
R9 and R9' are each independently selected from the group consisting of hydrogen, halogen, Cι-4-alkoxy, Cι-4-alkyl, -CN, -OCF3, -CONH2 and -CSNH2;
R6' is hydrogen, Cι-6-alkyl;
R3 is selected from the group consisting of hydrogen, Ci-
5-alkyl, C2-5 _alkenyl and C2-5~alkynyl; n is O, 1 or 2; m is 0, 1 or 2; p is 0, 1 or 2; q is 1 or 2; r is 0, 1 or 2; is a single or double bond; and pharmaceutically acceptable salts and solvates thereof.
Preferred compounds are those wherein R10' is propargyl. The present invention further provides a formulation comprising a compound of Formula I and one or more carriers or diluents therefor.
Additionally, the present invention provides a method for treating a condition which is mediated by a muscarinic receptor comprising administering an effective amount of a compound of Formula I to a mammal in need of such treatment.
It is to be understood that the invention extends to each of the stereoisomeric forms of the compounds of the present invention as well as the pure diastereomeric, pure enatiomeric, and racemic forms of the compounds of this invention. As used herein the term "treating" includes prophylaxis of a physical and/or mental condition or amelioration or elimination of the developed physical and/or mental condition once it has been established or alleviation of the characteristic symptoms of such condition.
As used herein the phrase "interacting with a muscarinic cholinergic receptor" shall include compounds which block muscarinic cholinergic receptors or modulate such receptors. The phrase shall include the effect observed when compounds act as agonists, partial agonists and/or antagonists at a muscarinic cholinergic receptor. As used herein the phrase "a condition which is mediated by a muscarinic receptor" shall refer to a condition which can be treated by administering a compound which acts as a muscarinic receptor antagonist, agonist, or mixed agonist at a muscarinic receptor. Such conditions shall include, but are not limited to, Alzheimer's disease, severely painful conditions, glaucoma, psychosis, anxiety, mania, bipolar disorder, schizophrenia or schizophreniform conditions, depression, sleeping disorders, epilepsy, cerebral ischemia, and gastrointestinal motility disorders. As used herein, the term "halogen" means Cl,
Br, F, and I. Especially preferred halogens include Cl, Br, and I. A particularly preferred halogen is Cl.
As used herein the phrase "one or more selected from" shall more preferredly refer to from 1-3 substituents. The term shall further preferredly refer to from 1-2 substituents.
As used herein, the term "aryl" has the meaning commonly attributed to the term by the artisan. Thus the term means molecules whose ring structure is characteristic of benzene, naphthalene, phenanthrene, anthracene, and the like. For example, an aryl radical could be, but is not limited to, phenyl, benzyl, naphthylene, and the like.
As used herein, the term "h+" means an alkoxide metal. As used herein, the term "alkoxide metal" means a metal suitable for alkoxide formation. Such alkoxide metals include, but are not limited to, Li+, K+, Na+, Cs+, and Ca++. Especially preferred alkoxide metals include Li+, K+, and Na+.
As used herein, the phrase "5 or 6 member heterocyclic group" means a group containing from one to four N, 0 or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with Cι-6-alkyl, -CF3, phenyl, benzyl or thienyl, or a carbon atom in the heterocyclic group together with an oxygen atom form a carbonyl group, or which heterocyclic group is optionally fused with a phenyl group. The phrase "5 or 6 membered heterocyclic group" includes, but is not limited to, 5-membered heterocycles having one hetero atom (e.g. thiophenes, pyrroles, furans) ; 5-membered heterocycles having two heteroatoms in 1,2 or 1,3 positions (e.g. oxazoles, pyrazoles, imidazoles, thiazoles, purines) ; 5-membered heterocycles having three heteroatoms (e.g. triazoles, thiadiazoles) ; 5-membered heterocycles having 3- heteroatoms; 6-membered heterocycles with one heteroatom (e.g. pyridine, quinoline, isoquinoline, phenanthrine, 5, 6-cycloheptenopyridine) ; 6-membered heterocycles with two heteroatoms (e.g. pyridazines, cinnolines, phthalazines, pyrazines, pyrimidines, quinazolines) ; 6- membered heterocycles with three heteroatoms (e.g. 1,3,5- triazine) ; and 6-member heterocycles with four heteroatoms. Particularly preferred are thiophenes, pyridines, and furans.
The terms "Cn'-C4 alkyl" wherein n'can be 1 or 2, as used herein, represent a branched or linear alkyl group having from one to 4 carbon atoms. Typical C1-C4 alkyl groups include, but are not limited to, methyl, ethyl, n- propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl and the like.
The term "C1-C4 alkoxy" refers to a carboxy group such as, but not limited to, methoxy, ethoxy, propoxy, butoxy, and the like. The alkoxy substituent is attatched to the parent molecule through the oxygen atom of the alkoxy group.
Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically-acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are known to the skilled artisan. The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
As described in the following Schemes, the following substituents have the meaning as follows unless otherwise indicated: W is oxygen or sulphur;
R is selected from the group consisting of hydrogen, amino, halogen, NHR6, NR6R7, R4, -OR4, -SR4, -SOR4, -S02R4, C3-ιrj-cycloalkyl, C4_i2~ (cycloalkylalkyl) , -Z-C3-10- cycloalkyl and -Z-C4-12- (cycloalkylalkyl) ; R4 is selected from the group consisting of Cι-15-alkyl, C2-I5~alkenyl and C2-I5~alkynyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen (s), -CF3, -
CN, Y, phenyl and phenoxy wherein phenyl or phenoxy is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, C1-4- alkyl, Cι-4-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, Cχ-4- alkyl, Cι-4-alkoxy, -OCF3, -CF3, -CONH2 and -CSNH2; or R is selected from the group consisting of -OR5Y, -SR5Y, 0R5-Z-Y, -SR5ZY, -0-R5-Z-R4 and -S-R5-Z-R4 ' "
Z is oxygen or sulphur, R5 is Cι-15-alkyl, C2-i5-alkenyl, and C2-i5~alkynyl;
Y is a 5 or 6 membered heterocyclic group;
G is selected from one of the following azacyclic or azabicyclic ring systems:
Figure imgf000010_0001
or G is optionally substituted C3-C8 cycloalkyl wherein the cycloalkyl substituents are selected from R1 and R2; or optionally substituted Ci-e-alkyl wherein the substitution is -NR6R7'*
R6 and R7 independently are selected from the group consisting of hydrogen and Cι-6 _alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring; R1 and R2 independently are selected from the group consisting of hydrogen, Cι-15-alkyl, C2-5_alkenyl, C2-5- alkynyl, Cι-ιrj-alkoxy, and Cι-5-alkyl substituted with one or more independently selected from the group consisting of -OH, -COR6', CH2-0H, halogen, -NH2, carboxy,
Figure imgf000011_0001
and phenyl;
R9 and R9' are each independently selected from the group consisting of hydrogen, halogen, Cι-4-alkoxy, Cι-4-alkyl,
-CN, -OCF3, -CONH2 and -CSNH2; R6' is hydrogen, Cι-6-alkyl;
R3 is selected from the group consisting of hydrogen, Ci-
5-alkyl, C2-5~alkenyl and C2-5-alkynyl; n is 0, 1 or 2; m is 0, 1 or 2; p is 0, 1 or 2; q is 1 or 2; r is 0, 1 or 2; is a single or double bond.
The compounds of this invention can be prepared using the chemical processes illustrated in Scheme I' and Scheme I. The starting materials for the illustrated process are commercially available or may be prepared using methods known to the skilled artisan.
Scheme I'
Figure imgf000012_0001
Figure imgf000013_0001
As used in Scheme I, R, h+, and G are as defined supra . As used in Scheme I, the term "Hal" refers to Cl and Br. Preferred oxidizing agents for the process of Scheme I include oxone and sodium periodate. Oxone is an especially preferred oxidizing agent for the process of Scheme I. Compounds of Formula 3, as illustrated in Scheme I wherein the OR group is replaced by an R4 group, can be prepared using methods well known in the art. See for example, U.S. Patent Number 5,043, 345. Further, compounds of Formula I may be prepared using the process illustrated m the following Schemes II and II'
Scheme II'
Figure imgf000014_0001
Scheme IT
Figure imgf000014_0002
As used in Scheme II and II', P may be hal or SO2R9; Q may be N, O or S; R24 is selected from the group consisting of hydrogen, R4, R5, R6, and R7; R25 is selected from the group consisting of SOR4 and SO2R4; all other meanings are as defined supra .
Additional compounds of Formula I may be prepared using the process illustrated by Scheme III. Scheme HI
Figure imgf000015_0001
reduction
Figure imgf000015_0002
As used in Scheme III, Hal, W, r, and G are as defined supra . As used in Scheme III, R22 and R23 are independently selected from the group consisting of hydrogen, R6 and R7.
Certain intermediates of the present invention may be prepared using the process illustrated in Scheme IV.
Scheme IV
Figure imgf000015_0003
9 10 11
As used in Scheme IV, R8, Si, R10,R1:L, R12, R13, R14, R15', R15 and R16 are as defined supra . For example, R8N[ (R10R11R12Si) (R13R14R15'Si) may be, but is not limited to lithium bis (tri-2-propylsilyl)amide, sodium bis (trimethylsilyl)amide, potassium bis (trimethylsilyl)amide, lithium bis(tri-2- propylsilyl)amide, sodium bis (ethyldimethylsilyl)amide, potassium bis (1-propylethylmethylsilyl)amide, lithium bis (tri-phenylsilyl) amide, sodium bis(tri- phenylmethylsilyl) amide, potassium bis (2-butyl-2- propylmethylsilyl) amide, lithium (tri-2-propylsilyl) (2- butyldiethylsilyl) amide, sodium
(trimethylsilyl) (triphenylsilyl) amide, potassium (dimethyl phenylsilyl) (ethyldimethylsilyl) amide, and the like. Most preferably, R15 and R16 are each hydrogen when the process of Scheme III is used for preparing a compound of 11 from a compound of 10. The intermediate 10 may be nitrosated using standard nitrosating procedures. A preferred nitrosating agent is isoamyl nitrite; however, other known nitrosating agents are appropriate. As used in Scheme III, the term "Cu(Br,I)" refers to copper (I) bromide, copper (II) bromide, or copper (I) iodide. The artisan will recognize that the copper (I) bromide, copper (II) bromide, or copper (I) iodide reagent shall determine the substitution on the product of the process illustrated in Scheme III.
Certain compounds of this invention may more preferably be prepared by a process using a hydroxyalkylamine (G-OH) wherein G has the meaning defined supra , in the presence of a phosphorus (III) compound and a diester of azodicarboxylate to give the 1,2,5- thiadiazoyloxyalkylamine as illustrated by Scheme V and V ,
Scheme V
Figure imgf000016_0001
Schβme V
Figure imgf000017_0001
/
COzR3'
The G group is 2-aza-bicyclo [2.2.1]heptane. The R'is selected from the group consisting of -OR4 and - SR4
R4 is selected from the group consisting of Cι-15-alkyl, C2-i5-alkenyl, C2-i5_alkynyl and 5-membered heterocycle, each of which is optionally substituted with one or more independently selected from the group consisting of halogen(s), -CF3, -CN, Y, phenyl and phenoxy wherein phenyl or phenoxy is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, Cι_4-alkyl, Cι-4-alkoxy, -OCF3, or -CF3; or
R' is phenyl or benzyloxycarbonyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, C1-4- alkyl, Cι-4-alkoxy, -OCF3, and -CF3; or
R' selected from the group consisting of -OR5Y, -SR5Y,
OR5-Z-Y, -SR5ZY, -0-R5-Z-R4 and -S-R5-Z-R4 '" Z is oxygen or sulphur;
R5 is selected from the group consisting of Cι-15-alkyl,
C2-i5-alkenyl, and C2-I5~alkynyl;
Y is a 5-membered heterocyclic group;
R1' is selected from the group consisting of phenyl, Cι_ 15-alkyl, C2-5-alkenyl, C2-5~alkynyl and (NR2')3;
R2' and R3' are independently selected from the group consisting of hydrogen, Cι-15-alkyl, C2-5~alkenyl, C2-5- alkynyl, and Cι-5-alkyl substituted with one or more selected from the group consisting of halogen and phenyl; W is oxygen or sulphur;
R6, and R7 independently are Cι-6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 independently are selected from the group consisting of hydrogen, Cι-15-alkyl, C2-5-alkenyl, C2-5- alkynyl, Cι-10-alkoxy, and Cι-5-alkyl substituted with one or more independently selected from the group consisting of -OH, -COR6', CH2-0H, halogen, -NH2, carboxy,
Figure imgf000018_0001
and phenyl;
R9 and R9' are each independently selected from the group consisting of hydrogen, halogen, Cι-4-alkoxy, Cι-4-alkyl,
-CN, -OCF3, -CONH2 and -CSNH2;
R6' is hydrogen or C1-C3 alkyl;
R3 is selected from the group consisting of Cι-5-alkyl,
C2-5~alkenyl and C2-5 _alkynyl; n is O, 1 or 2; m is 0, 1 or 2; p is O, 1 or 2; q is 1 or 2; r is 0, 1 or 2; is a single or double bond.
Preferred R1' groups include phenyl, Cι-15-alkyl, and (NR2')3. The process of Scheme IV is particularly advantageous because the process provides a method for inverting the stereochemistry at the carbon bearing the hydroxyl group in G.
Another new process illustrated by Schemes VI and VI', involves the sequential reaction of 3, 4-dihydroxy- 1, 2, 5-thiadiazole with G-OH wherein G is defined as defined supra , in the presence of a phosphorous (III) compounds and a diester of azodicarboxylate to give an unisolated hydroxy- 1, 2, 5-thiadiazole ether I*' followed by reaction of I' ' with R4OH where R4 is defined as supra , with phosphorous (III) compounds and a diester of azodicarboxylate to give the diethers of 3, 4-dihydroxy-l,2, 5-thiadiazole which are useful as muscarinic agonists and antagonists. (See, Org. Prep . & Procedures 1969, 1 , 255-258) The substituents illustrated in Scheme VI are as defined supra .
Scheme VI'
OH
Figure imgf000019_0001
COJJR2, P(R' )3
N .co^2 P(R] )3
"3 2 R4OH n,o,c' R4OH
Figure imgf000019_0002
Scheme VI
C
Figure imgf000020_0001
Alternatively, the order of addition of the alcohols may be reversed as shown above to give unisolated hydroxy-1,2, 5-thiadiazole ether II which is subsequently converted to the same final muscarinic active compound.
The process illustrated by Scheme VII encompases the reaction of a phenol or hydroxyheteroaryl compound with compound III in the presence of a phosphorus(III) compound and a diester of azodicarboxylate to give compound IV.
Scheme VII
Aryl . -OH
Figure imgf000020_0002
R« OAryl
IV (OHeteroaryl)
Figure imgf000020_0003
In compound III, G(CH2)r w is 2-Aza- bicyclo[2.2.1]heptane and R6' is selected from the group consisting of R7, -OR7, -SR7, -SOR7, -S02R7, C3-10- cycloalkyl, C4-12- (cycloalkylalkyl) , -Z-C3-ιo-cycloalkyl and -Z-C4-12- (cycloalkylalkyl) ;
R7 is Cι-15-alkyl, C2-i5~alkenyl, C2-i5_alkynyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen (s), -CF3, -CN, Y, phenyl and phenoxy; wherein phenyl or phenoxy is optionally substituted with one or more selected from the group consisting of halogen, -CN, C1-4- alkyl, Cι-4-alkoxy, -OCF3, and -CF3; provided that at least one alkyl atom of R6' is substituted with a hydroxyl group or R6'is a substituent selected from the group consisting of -OR8Y, -SR8Y, OR8-Z-Y, -SR8ZY, -0- R8-Z-R7 and -S-R8-Z-R7 wherein each -0R8Y, -SR8Y, OR8-Z-Y, - SR8ZY, -0-R8-Z-R7 and -S-R8-Z-R7 is substituted with a alkylhydroxyl;
Y is a 5 or 6 membered heterocyclic group; Z is oxygen or sulphur; R8 is Cι-15-alkyl, C2-i5~alkenyl, C2-i5~alkynyl; aryl and heteroaryl is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, Cι-4-alkyl, Cι-4-alkoxy, Cι-4-alkylthio, C1-4- alkylsulfone, Cι-4-alkylsulfoxide, -OCF3, NO2, N(R7)2, and - CF3; heteroaryl group is a 5 or 6 membered heterocycle containing one to four N, 0, or S atoms or a combination thereof.
Another process of this invention, illustrated by Scheme VIII, is the synthesis of 3-hydroxy-4-alkylthio- 1, 2, 5-thiadiazoles by treating 3-halo-4-alkylthio-l, 2, 5- thiadiazoles with aqueous alkaline metal hydroxides in the presence or absence of a dipolar aprotic solvent. In this scheme, Hal has the meanings defined supra , and M is an alkali metal, W is 0 or S. Scheme VI I I
Figure imgf000022_0001
RR is hydrogen, R4, C3_ιo-cycloalkyl, C4-12- (cycloalkylalkyl) , R4-Z-C3-ι0-cycloalkyl and R4-Z-C4_12- (cycloalkylalkyl) ; W is oxygen or sulfur;
R4 is selected from the group consisting of Cι_i5-alkyl, C2-15~alkenyl, and C2-i5-alkynyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen(s), -CF3, Y, phenyl and phenoxy; wherein phenyl or phenoxy is optionally substituted with one or more selected from the group consisting of halogen, Cι-4-alkyl, Cι-4-alkoxy, and
-CF3; or
RR is phenyl or benzyloxycarbonyl, each of which is optionally substituted with one or more selected from the group consisting of halogen, Cι-4-alkyl, Cι-4-alkoxy, and
-CF3; or
RR is R4-OR5Y, R4-SR5Y, R4-OR5-Z-Y, R4-SR5ZY, R4-0-R5-Z-R4 or R4-S-R5-Z-; Z is oxygen or sulphur;
R5 is selected from the group consisting of Cι-15-alkyl, C2-i5_alkenyl, and C2-i5-alkynyl;
Y is a 5 or 6 membered heterocyclic group; and
R6, and R7 independently are hydrogen, Cι-6 _alkyl, or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 independently are hydrogen, C]__i5-alkyl, C2-5- alkenyl, C2-5~alkynyl, Cι-10-alkoxy, Cι-5-alkyl substituted with -OH, -COR6', CH2-OH, halogen, -NH2, carboxy, or phenyl;
R6' is hydrogen or C1-C3 alkyl;
W is 0 or S; Hal is selected from Cl, Br, F, I, and if W is O then Hal may be SO2R4' ;
R4' is C1-C3 alkyl or phenyl.
The compounds (11) are useful intermediates for the preparation of 1, 2, 5-thiadiazole compounds. The artisan will recognize that the intermediates 11 are useful for preparing 1, 2, 5-thiadiazole compounds as illustrated by the processes of Schemes I, II, and III. When the G substituent contains a secondary nitrogen protected by a protecting group, the protecting group may be removed using standard methods known to the skilled artisan. An especially preferred protecting group is carbamate. One particularly useful reference concerning protecting groups is Greene, Protecting Groups in Organic Synthesis, (John Wiley & Sons, New York, 1981) .
The concentration of the reactants is not critical. The art worker can alter the concentration of the reactants to achieve the desired rate of reaction and product yield.
The length of time for carrying out the processes described are not critical. As is always the case in chemistry, the rate of the reaction depends on a variety of factors, such as the temperature and the exact compound which is to be prepared. The course of the reaction may be followed using methods such as thin layer chromatography (TLC) , high performance liquid chromatography (HPLC) , gas chromatography (GC) and nuclear magnetic resonance spectroscopy (NMR) to detect the degree of completion of the reaction. The operator may obtain maximum yields using the process by extending the reaction time. Alternatively, the operator may wish to obtain maximum throughput by cutting off the reaction at the point at which it reaches an economical degree of completion.
When the product of a step in the following process is an oil, it may be isolated by standard methods. Such methods include distillation, flash chromatography, HPLC and the like.
As used herein the term "malfunctioning of the muscarinic cholinergic system" shall have the meaning accepted by the skilled artisan. For example the term shall refer to, but is not in any way limited to, conditions such as glaucoma, psychosis, schizophrenia or schizophreniform conditions, depression, sleeping disorders, epilepsy, and gastrointestinal motility disorders. Other such conditions include Alzheimer's Disease and incontinence.
The pharmacological properties of the compounds of the invention can be illustrated by determining their capability to inhibit the specific binding of 3H- Oxotremorine-M (3H-Oxo) . Birdsdall N.J.M., Hulme E.C, and Burgen A.S.V. (1980) . "The Character of Muscarinic Receptors in Different Regions of the Rat Brain". Proc. Roy. Soc. London (Series B) 207,1.
3H-Oxo labels muscarinic receptor in the CNS
(with a preference for agonist domains of the receptors) . Three different sites are labeled by 3H-Oxo. These sites have affinity of 1.8, 20 and 3000 nM, respectively. Using the present experimental conditions only the high and medium affinity sites are determined.
The inhibitory effects of compounds on 3H-oxo binding reflects the affinity for muscarinic acetylcholine receptors.
All preparations are performed at 0-4°C unless otherwise indicated. Fresh cortex (0.1-1 g) from male Wistar rats (150-250 g) is homogenized for 5-10 seconds in 10 mL 20 nM Hepes pH: 7.4, with an Ultra-Turrax homogenizer. The homogenizer is rinsed with 10 mL of buffer and the combined suspension centrifuged for 15 min. at 40,000 x g. The pellet is washed three times with buffer. In each step the pellet is homogenized as before in 2 x 10 mL of buffer and centrifuged for 10 min. at 40, 000 x g.
The final pellet is homogenized in 20 mM Hepes pH: 7.4 (100 mL per g of original tissue) and used for binding assay. Aliquots of 0.5 mL is added 25 μL of test solution and 25 μL of 3H-Oxotremorine (1.0 nM, final concentration) mixed and incubated for 30 min. at 25°C. Non-specific binding is determined in triplicate using arecoline (1 μg/mL, final concentration) as the test substance. After incubation samples are added 5 mL of ice-cold buffer and poured directly onto Whatman GF/C glass fiber filters under suction and immediately washed 2 times with 5 mL of ice-cold buffer. The amount of radioactivity on the filters are determined by conventional liquid scintillation counting. Specific binding is total binding minus non specific binding.
Test substances are dissolved in 10 mL water
(if necessary heated on a steam-bath for less than 5 min.) at a concentration of 2.2 mg/mL. 25-75% inhibition of specific binding must be obtained before calculation of IC50. The test value will be given as IC50 (the concentration (nM) of the test substance which inhibits the specific binding of 3H-oxo by 50%) . IC50 = (applied test substance concentration) x(Cx/C0- Cx)nM where C0 is specific binding in control assays and Cx is the specific binding in the test assay. (The calculations assume normal mass-action kinetics) .
Furthermore the pharmacological properties of the compounds of the invention can also be illustrated by determining their capability to inhibit 3HPRZ (pirenzepine, [N-methyl-3H] ) binding to rat cerebral cortex membranes. Pirenzepine binds selectively to subtype of muscarinic receptors. Historically the type is named the Mi-site, whereas pirenzepine sensitive site would be more appropriate. Although selective for Mχ-sites pirenzepine also interact with M2~sites.
All preparations are performed at 0-4°C unless otherwise indicated. Fresh cortex (0.1-1 9) from male Wistar rats (150-200 g) is homogenized for 5-10 s in 10 mL 20 mM Hepes pH: 7.4, with an Ultra-Turrax homogenizer. The homogenizer is rinsed with 2 x 10 mL of buffer and the combined suspension centrifuged for 15 min. at 40,000 x g. The pellet is washed three times with buffer. In each step the pellet is homogenized as before in 3 x 10 mL of buffer and centrifuged for 10 min. at 40,000 x g.
The final pellet is homogenized in 20 mM Hepes pH: 7.4 (100 mL per g of original tissue) and used for binding assay. Aliquots of 0.5 mL is added 20 μl of test solution and 25 μL of 3HPRZ (1.0 nM, final cone), mixed and incubated for 60 min. at 20°C. Non-specific binding is determined in triplicate using atropine (1 , μg/mL, final cone.) as the test substance. After incubation samples are added 5 mL of ice-cold buffer and poured directly onto Whatman GF/C glass fiber filters under suction and immediately washed 2 times with 5 mL of ice- cold buffer. The amount of radioactivity on the filters are determined by conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.
Test substances are dissolved in 10 mL water, at a concentration of 0.22 mg/mL. 25-75% inhibition of specific binding must be obtained before calculation of IC50. The test value will be given as IC50 (the concentration (nM) of the test substance which inhibits the specific binding of 3HPRZ by 50%) . IC50 = (applied test substance concentration) x (Cx/C0 _ Cx)nM where C0 is specific binding in control assays and Cx is the specific binding in the test assay. (The calculations assume normal mass-action kinetics) .
Additionally, the pharmacological activity and tendency to produce salivation can be determined or verified using the following methods:
Compounds can be tested using the following A9 L-ml assay- Stimulation of phosphoinositol hydrolysis in A9 L-ml cells:
A9-L-ml cells were cultured to confluence in 75 mL flasks containing Dubecco's modified essential media. Cells were prelabeled with 1 μCi/mL of myo[2-3H] inositol (Amersham Ine, 16.3 Ci/mmol) for 48 h prior to assay. On the day of assay, cells were detached using a 30 s exposure to 0.25% trypsin in 1 mM EDTA. The cells were collected by centrifugation (300xg for 5 min) and resuspended in oxygenated HEPES buffer containing 10 mM LiCl, 142 mM NaCl, 5.6 mM KCl, 2.2 mM CaCl2/ 1 mM MgCl2, 3.6 mM NaHCθ3, 5.6 mM D-glucose, and 30 mM sodium HEPES at pH 7.4. Cells were incubated at 37 C for 45 miru in the presence of varying concentrations of drug. The reaction was terminated by the addition of 3 mL of ice cold 10 mM LiCl, sonicated, and centrifugated at 20,000xg. The supernatent was decanted over a Accell QMA anion exchange SEP-PAK cartridge in the formate form (Waters
Associates, Milford, MA) . The cartridges were washed with 10 mL of H2O followed by 10 mL of 5 mM sodium borate.
[3H]PI was eluted directly into scintillation vials for counting with 4 mL of 0.1 ammonium formate/0.01 mM formic acid/5 mM sodium borate. Data is expressed as the percent of total [3H]PI stimulated in the presence of 1 mM carbachol. Half-maximal values (EC50) were determined from the mean of seven point curves using a four parameter logistic model.
Salivation in mice:
Mice weighing 20 to 30 g were used for salivation testing. Mice, in groups of five, were injected i.p. with 10 mg/kg doses of compound dissolved in distilled water. After, 30 min, salivation and tremor were scored on a scale of 0, 1, or 2, where 0 = no effect, 1 = moderate salivation or tremor, and 2 = marked salivation or tremor. Those compounds producing an average score of 1 were tested at half log lower doses until a score lower than 1 was achieved. The lowest dose of compound producing a score of 1 was expressed at the minimum effective dose (MED) .
The compounds of the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.05 to about 100 mg, preferably from about 0.1 to about 100 mg, per day may be used. A most preferable dosage is about 0.1 mg to about 70 mg per day. In choosing a regimen for patients suffering from diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system it may frequently be necessary to begin with a dosage of from about 20 to about 70 mg per day and when the condition is under control to reduce the dosage as low as from about 0.1 to about 10 mg per day. The exact dosage will depend upon the mode of administration, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or prescribing caregiver in charge.
The route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, depot, subcutaneous, intravenous, intramuscular or intranasal, the oral route being preferred.
Typical compositions include a compound of formula I or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art. The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.
For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.
Generally, the compounds are dispensed in unit form comprising from about 0.1 to about 100 mg in a pharmaceutically acceptable carrier per unit dosage.
The compounds of this invention may be suitable for administration to an animal. Such animals include both domestic animals, for example livestock, laboratory animals, and household pets, and non-domestic animals such as wildlife. More preferredly, the animal is a vertebrate. Most preferredly, a compound of this invention shall be administered to a mammal. It is especially preferred that the animal is a domestic mammal or a human. The most preferred mammal is a human. For such purposes, a compound of this invention may be administered as a feed additive.
In order to more fully illustrate the operation of this invention, the following formulation examples are provided. The examples are illustrative only, and are not intended to limit the scope of the invention in any way.
Formulation 1 A typical tablet, appropriate for use in this method, may be prepared using conventional techniques and may contain:
Amount per Conce:
Tablet by Wι
1 \ 9 "t- I \ a compound of this invention 5.0 mg 4.7
Lactosum 67.8 mg Ph. Eur. 64.2
Avicel® 31.4 mg 29.8
Amberlite® 1.0 mg 1. .0 magnesium stearate 0.25 mg 0.3 105.45 mg 100
Formulation 2
Hard gelatin capsules are prepared using the following ingredients:
Amount per Concentration Tablet by Weight
(%)
a compound of this invention 0.1 mg 0.05 starch dried 200 mg 95.2 magnesium stearate 10 mg 4.8 210.1 mg 100
The above ingredients are mixed and filled into hard gelatin capsules in 210.1 mg quantities. Formulation 3 Suspensions each containing 1 mg of medicament per 5 mL dose are as follows:
Amount per 5mL of suspension a compound of this invention 1 mg
sodium carboxymethyl cellulose 50 mg
syrup 1.25 mL
benzoic acid solution 0.10 mL
flavor q.v.
color q.v.
water q.s. to 5 mL
The medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color is diluted with some of the water and added to the paste with stirring.
Sufficient water is then added to produce the required volume.
The intermediates and processes of the present invention are useful for preparing compounds having beneficial muscarinic receptor activity. The compounds of the present invention have such useful muscarinic receptor activity. Certain compounds and conditions within the scope of this invention are preferred. The following conditions, invention embodiments, and compound characteristics listed in tabular form may be independently combined to produce a variety of preferred compounds and process conditions. The following list of embodiments of this invention is not intended to limit the scope of this invention in any way.
Some prefered characteristics of compounds of formula I are:
A) R9 is chloro and R8 is hydrogen;
B) R9 is chloro and in the para position;
C) the Formula I compound is endo;
D) R8 is ethyl or isopropyl;
E) R9 is methoxy;
F) W is 0;
G) W is S;
H) a compound of the formula II
Figure imgf000033_0001
wherein R is selected from the group consisting of:
Figure imgf000034_0001
i-Pr
Figure imgf000035_0001
I) A compound having a side chain named in letter H above herein, wherein W is an oxygen group.
J) a compound wherein R8 is ethyl and R9 is fluoro and R9 is located in the para position.
K) G is an azabicyclo [2.2.1] heptane.
The invention will now be described in further detail with reference to the following examples. The examples are provided for illustrative purposes, and are not to be construed as limiting the scope of the invention in any way. Preparation 1
3-Chloro-4- (1-butylthio) -1,2, 5-thiadiazole
Cyanogen (36 g, 0.69 mol) was bubbled into ether (250 mL) maintained at -10°C. To the solution was added dropwise diethylamine (3 mL) followed by dropwise addition of 1-butylthiol (47 mL, 0.64 mol) at such a rate that the temperature did not exceed -5°C. The reaction was maintained below 0°C for 5 h then stirred at ambient overnight. Ether was distilled from the reaction until the pot temperature reached 50°C. The reaction was cooled to ambient and then added dropwise to a solution of sulfur monochloride (55 mL, 0.688 mol) in DMF (50 mL) that was cooled to 5°C. Cooling was removed and reaction was stirred overnight. The reaction was cooled in an ice- water bath and excess sulfur monochloride destroyed by careful addition of H2O while maintaining the temperature below 40°C. The liquid was decanted from the semi-solid sulfur precipitant and the sulfur residue triturated with hexane. The aqueous fraction was extracted with hexane (3 X) and the combined extracts and triturants were washed with H2O, aqueous NaHC03, brine, dried, and the solvent evaporated. The residue was distilled at 2 mm Hg to give a yellow liquid (24.6 g) , b.p. 105-110°C. (Compound 1) .
Preparation 2
3-Butylthio-4-hydroxy-l, 2, 5-thiadiazole
A solution of Compound 1 (20.9 g) , DMSO (20 mL) and 2N NaOH (205 mL) was headed to reflux overnight. The solution was cooled to 15 °C and concentrated HCl was added until the pH was 1. The solid was collected, washed with water, and dried to give a solid (17.68 g) . Recrystallization from heptane gave white crystals, m.p. 72-72.5 °C (Compound 300) . Preparation 3
(±) Sxo-3-Butylthio-4- (1-azabicyclo [2.2.1]heptyl-3-oxy) -
1,2, 5-thiadiazole
A solution of triphenylphosphine (0.7 g) and Compound 300 (0.5 g) in THF (20 mL) was cooled in ice-water. Diethyl diazodicarboxylate (0.4 mL) was added dropwise followed by addition of (±) endo-3-hydroxy-l- azabicyclo [2.2.1]heptane (0.29 g) . Cooling was removed and after 1 h the solvent was evaporated. The residue was suspended in cold water, acidified, and extracted with ether. The aqueous fraction was made basic and extracted with EtOAc. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography eluting with 5%-EtOH-0.5% NH4OH-CHCI3 to give a clear oil. The HCl salt crystallized from EtOAc as white crystals (0.44 g) , m.p. 147-148 °C. (Compound
301) .
Preparation 4
3-Propylthio-4-hydroxy-l, 2, 5-thiadiazole
A mixture of 3-chloro-4-propylthio-l, 2, 5-thiadiazole (10 g) , 2 N NaOH (100 mL) , and DMSO (10 mL) was heated to reflux for 24 h. The solution was cooled and extracted with ether. The aqueous fraction was acidified with cone. HCl and cooled in ice-water for 3 h. The resulting solid was collected, washed with a small amount of cold water to give a white solid (8.15 g) . Recrystallization from heptane gave white crystals, m.p. 84-85 °C. Preparation 5
(±) £xo-3-Propylthio-4- ( 1-azabicyclo [2.2.1 ] heptyl-3-oxy) -
1,2, 5-thiadiazole
A solution of triphenylphosphine (3.96 g) and 3- propylthio-4-hydroxy-l, 2, 5-thiadiazole (2.62 g) in THF (110 mL) was cooled in ice-water. Diethyl diazodicarboxylate (2.27 mL) was added dropwise followed by addition of (±) endo-3-hydroxy-1- azabicyclo [2.2.1] heptane (1.64 g) . Cooling was removed and after 23 h the solvent was evaporated. The residue was suspended in cold water, acidified, and extracted with ether. The aqueous fraction was made basic and extracted with ether. The extracts were dried, the solvent evaporated, and the residue purified by radial chromatography eluting with 5%-EtOH-0.5% NH4OH-CHCI3 to give a clear oil, 2.69 g. The HCl salt crystallized from CHCl3-ether as white crystals, m.p. 176-177 °C.
Example 1
(±) £xo-3-Propylsulfonyl-4- (1-azabicyclo [2.2.1 ] heptyl-3- oxy) -1,2, 5-thiadiazole
(±) £xo-3-Propylthio-4- ( 1-azabicyclo [2.2.1] heptyl-3-oxy) - 1, 2, 5-thiadiazole (2.0 g) was dissolved in a mixture of IN HC1J9 mL) and H2O (15 mL) and cooled in ice-water.
To the solution was added dropwise a solution of Oxone (6.94 g) in H2O (35 mL) . Cooling was removed and the reaction stirred 5.5 h. Excess oxidant was destroyed with sodium bisulfite and the reaction again cooled in ice-water. The solution was made basic with 5 N NaOH and extracted with EtOAc to give a yellow oil (2.01 g) . Example 2
(±) ffxo-3- (3- (4-Chlorophenyl)propynyloxy-4- (1- azabicyclo [2.2.1]heptyl-3-oxy) -1,2, 5-thiadiazole
A solution of 3- (4-chlorophenyl)propynol (0.25 g) in THF (15 mL) is cooled in ice-water as potassium tert-butoxide (0.17 g) is added. After about 10 min, (±) exo-3-propylsulfonyl-4- (1-azabicyclo [2.2.1]heptyl-3- oxy) -1, 2, 5-thiadiazole (0.2 g) is added and the reaction stirred 1 h. The reaction is quenched with 5 N HCl (1 mL) and the solvent evaporated. The residue is suspended in cold water and extracted. The aqueous solution is made basic and extracted. The extracts are dried, the solvent is evaporated, and the residue converted to a salt that is recrystallized.
EXAMPLE 3
Endo-3- (3-butylthio-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate
A solution of endo-3-hydroxy-l-azabicyclo [2.2.1]heptane, (J.Med.Chem. 1992, 35, 2392-2406), (225 mg, 2.0 mmol) in dry THF (5 ml) was created with 95% potassium t-butoxide
(260 mg, 2.0 mmol) . After 30 min., the reaction was cooled in ice-water. To the cold solution was added a single portion of 3-chloro-4-butylthio-l, 2, 5-thiadiazole (420 mg, 2.0 mmol) . Cooling was removed and after 4 h the reaction was heated to reflux for 1.5 h. The solvent was evaporated and the residue suspended in cold water and acidified with
4N HCl. The mixture was extracted with ether (2 x - discarded) . The aqueous phase was made basic and the mixture extracted with dichloromethane (3 x) . The dichlo- romethane extracts were washed with water, dried (MgSθ4), and the solvent evaporated. The residue was taken up in acetone, and the product precipitated with oxalic acid in acetone followed by ether to give 240 mg (32%) of the title compound. M.p. 125-126_C. Compound 1.
EXAMPLE 4
The following compound was made in the same manner as described in example 3 by using the reagents indicated.
Endo-3- (3-propylthio-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3-hydroxy-l- azabicyclo [2.2. l]heptane and 3-chloro-4-propylthio-l, 2, 5- thiadiazole. Yield: 38%. M.p. 136-137_C. Compound 2.
EXAMPLE 5
Endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate
A solution of endo-3- (3-propylthio-l, 2, 5-thiadiazol-4- yloxy) -1-azabicyclo [2.2.1] heptane, oxalate (example 2)
(4.1 g, 11.3 mmol) in water (30 ml) and IN HCl (13.5 ml) was cooled in ice-water. Oxone (10.5 g, 17.1 mmol) in water (60 ml) was added to the reaction over 10 min.
Cooling was removed and the reaction stirred for 16 h. The reaction was cooled in ice-water and then made basic with NH3. The mixture was extracted with ether (6 x) . The extracts were dried (MgSO^) and evaporated. The product was taken up in acetone and precipitated with oxalic acid in acetone to give 3.2 g (73%) . M.p. 168-169_C. Compound 3.
EXAMPLE 6
Endo-3- (3- [3- (4-fluorophenyl) -2-propynyl-l-oxy] -1,2,5- thiadiazol-4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate A suspension of sodium hydride (90 mg, 3.0 mmol) in dry
THF (30 ml) and 3- (4-fluorophenyl) -2-propyn-l-ol (225 mg,
1.5 mmol) was stirred at room temperature for 1 h under nitrogen. The reaction was then cooled in ice-water and added endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -
1-azabicyclo [2.2.1]heptane (303 mg, 1.0 mmol) . After 16 h the cold reaction was quenched with water and the product extracted with ether (3 x) . The extracts were dried (MgSθ4) and the solvent evaporated. The product was taken up in acetone and precipitated with oxalic acid in acetone followed by ether to give 180 mg (41%) of the title compound. M.p. 163-165_C. Compound 4.
EXAMPLE 7
The following compound was made in substantially the same manner as described in example 6 by using the reagents indicated:
Endo-3- (3- [3-phenyl-2-propynyl-l-oxy] -1,2, 5-thiadiazol-4- yloxy) -1-azabicyclo[2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1-azabi¬ cyclo [2.2.1]heptane, oxalate and 3-phenyl-2-propyn-l-ol . Yield: 81%. M.p. 158-159_C. Compound 5.
Endo-3- (3- [3- (3-methoxyphenyl) -2-propynyl-l-oxy] -1, 2, 5- thiadiazol-4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2.1]heptane, oxalate and 3- (3- methoxyphenyl) -2-propyn-l-ol. Yield: 47%. M.p. 142-143_C Compound 6.
Endo-3- (3- [3-methyl-2-butenyl-l-oxy] -1, 2, 5-thiadiazol-4- yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 3-methyl-2-buten-l- ol. Yield: 55%. M.p. 112-115 C. Compound 7. Endo-3- (3- [2-cyclopropylethyl-l-oxy] -1,2, 5-thiadiazol-4- yloxy) -1-azabicyclo [2.2. l]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and cyclopropylethanol Yield: 74%. M.p. 132-133_C. Compound 8.
Endo-3- (3- [4-fluorobenzyloxy] -1, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2.1]heptane, oxalate from endo-3-(3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 4-fluorobenzyl alcohol. Yield: 62% M.p. 144-145_C. Compound 9.
Endo-3- (3- [2-butenyl-l-oxy] -1,2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and crotyl alcohol. Yield: 67%. M.p. 129-131_C. Compound 10.
Endo-3- (3- [2-butynyl-l-oxy] -1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 2-butyn-l-ol. Yield: 73%. M.p. 194-196_C. Compound 11.
Endo-3- (3-methylthioethoxy-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo- [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 2-hydroxyethylme- thyl sulfide. Yield: 60%. M.p. 117-119_C. Compound 12.
Endo-3- (3-methoxyethoxy-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 2-methoxyethanol. Yield: 78%. M.p. 139-141_C. Compound 13. Endo-3- (3- [4-trifluoromethoxybenzyloxy] -1, 2, 5-thiadiazol- 4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. l]heptane, oxalate and 4- (trifluoromethoxy)benzyl alcohol. Yield: 77%. M.p. 116- 119_C. Compound 14.
Endo-3- (3- [4,4, 4-trifluorobutyl-1-oxy] -1, 2, 5-thiadiazol-4-yloxy) 1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. l]heptane, oxalate and 4, 4, 4-trifluorobutanol . Yield: 73%. M.p. 135-137_C. Compound 15.
Endo-3- (3- [2-fluoro-4- (trifluoromethyl) -benzyloxy] -1,2,5- thiadiazol-4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2.1]heptane, oxalate and 2-fluoro-4- (trifluoromethyl)benzyl alcohol. Yield: 73%. M.p. 112- 114_C. Compound 16.
Endo-3- (3- [4- (3-methoxyphenyl) -3-butyn-2-yloxy] -1, 2, 5- thiadiazol-4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2.l]heptane, oxalate and 4- (3- methoxyphenyl) -3-butyn-2-ol. Yield: 62%. M.p. 102-103_C. Compound 17.
Endo-3- (3- [3- (4-chlorophenyl) -2-propynyl-l-oxy] -1, 2, 5- thiadiazol-4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2. l]heptane, oxalate and 3- (4- chlorophenyl) -2-propyn-l-ol. Yield: 40%. M.p. 118-122_C. Compound 18.
Endo-3- (3- [1- (3-methoxyphenyl) -l-pentyn-3-yloxy] -1,2,5- thiadiazol-4-yloxy) -1-azabicyclo [2.2. l]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2.1]heptane, oxalate and l-(3- methoxyphenyl) -l-pentyn-3-ol. Yield: 25%. M.p. 98-101_C. Compound 19.
Endo-3- (3- [1- (3-methoxyphenyl) -4-methyl-l-pentyn-3- yloxy] -1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- butylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. l]heptane, oxalate and l-(3- methoxyphenyl) -4-methyl-l-pentyn-3-ol . Yield: 35%. M.p. 144-147_C. Compound 20.
Endo-3- (3- [2,2,2-trifluoroethyl-l-oxy]-l,2, 5-thiadiazol- 4-yloxy) -1-azabicyclo [2.2. ljheptane, oxalate from endo-3- (3-butylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 2,2,2- trifluoroethanol. Yield: 54%. M.p. 153-156_C. Compound 21.
Endo-3- (3-cyclobutylmethyloxy-l, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo[2.2. l]heptane, oxalate from endo-3- (3- butylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. ljheptane, oxalate and cyclobutyl methanol. Yield: 46%. M.p. 96-99_C. Compound 22.
Endo-3- (3- (3- (3-trifluoromethylphenyl) -2-propynyl-l-oxy) - 1,2, 5-thiadiazol-4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4- yloxy) -1-azabicyclo [2.2. l]heptane, oxalate (example 5) and 3- (3-trifluoromethylphenyl) -2-propyn-l-ol. M.p. 131- 135_C. Compound 23.
Endo- (Z) -3- (3- (5- (4-fluorophenyl) -3-methyl-2-penten-4-yn- 1-yloxy) -1,2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. l]heptane, oxalate and (Z)-5-(4- fluorophenyl) -3-methyl-2-penten-4-yn-l-ol . M.p. 174- 177_C. Compound 24.
Endo- (E)-3-(3-(5- (4-fluorophenyl) -3-methyl-2-penten-4-yn- 1-yloxy) -1,2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1] heptane, oxalate and (E)-5-(4- fluorophenyl) -3-methyl-2-penten-4-yn-l-yloxy) . M.p. 82- 84_C. Compound 25.
Endo-3- (3- (3-pyridyl) -2-propyn-l-yloxy) -1,2, 5-thiadiazol- 4-yloxy) -1-azabicyclo [2.2. Ijheptane, dioxalate from endo- 3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and (3-pyridyl) -2- propyn-1-ol. M.p. 136-139_C. Compound 26.
Endo- (E/Z) -3- (3- (5- (4-fluorophenyl) -2-penten-4-yn-l- yloxy) -1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 5- (4-fluorophenyl) - 2-penten-4-yn-l-ol. M.p. 185-188_C. Compound 27.
Endo-3- (3- (2-pyridyl) -2-propyn-l-yloxy) -1,2, 5- thiadiazol-4-yloxy) -1-azabicyclo [2.2.1]heptane, dioxalate from endo-3- (3-propylsulfonyl-l, 2, 5- thiadiazol-4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate and (2-pyridyl) -2-propyn-l-ol. M.p. 158-160_C. Compound 28.
Endo-3- (3- (3- (3-furyl) -2-propyn-l-yloxy) -1,2,5- thiadiazol-4-yloxy) -1-azabicyclo [2.2.1] heptane, oxalate from endo-3- (3-propylsulfonyl-l,2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2.1]heptane, oxalate and 3- (3-furyl) -2- propyn-1-ol. M.p. 146-148 C. Compound 29. Endo-3- (3- (2,2,3, 3, 4, 4, 4-heptafluorobutyl-1-oxy) -1,2,5- thiadiazol-4-yloxy) -l-azabicyclo[2.2.1] heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2. l]heptane, oxalate and 2,2,3,3,4,4,4- heptafluorobutan-1-ol. M.p.128-131_C. Compound 30.
Endo-3- (3- (3- (3-fluorophenyl) -2-propyn-l-yloxy) -1.2.5- thiadiazol-4-yloxy-1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2. l]heptane, oxalate and 3- (3- fluorophenyl) -2-propyn-l-ol . M.p. _C. Compound 31.
EXAMPLE 8
Endo-3- (3- (3, 3, 3-trifluoropropylthio) -1, 2, 5-thiadiazol- 4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate
A solution of endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-
4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate (300 mg, 0.76 mmol) and potassium carbonate (210 mg, 1.52 mmol) in
DMF (10 ml) was added sodium hydrosulphide (225 mg, 3.00 mmol) under N2. The solution was stirred at 80~100_C for
4 h. The solution was then cooled to room temperature and added potassium carbonate (1.05 g, 7.6 mmol) and 3,3,3- trifluoropropyl iodide (510 mg, 228 mmol) . After 10 min. ice-water and 6N HCl were added to pH 2.0. The aqueous phase was washed with ether (3 x) , then made basic with
NaOH to pH 11.0. The product was extracted with ether (3 x) , dried (MgSθ4) and the solvent evaporated. The residue was taken up in acetone and the product precipitated with oxalic acid in acetone followed by ether to give 230 mg (72%) of the title compound. M.p. 186-187 C. Compound 32. EXAMPLE 9
The following compounds were made in substantially the same manner as described in example 8 by using the reagents indicated.
Endo-3- (3- (4, 4, 4-trifluorobutylthio) -1,2, 5-thiadiazol-4- yloxy) -1-azabicyclo[2.2. l]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and trifluorobutyl bromide. Yield: 61%. M.p. 114-115_C. Compound 33.
Endo-3- (3- [4-cyanobenzylthio] -1,2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2.1] heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 4-cyanobenzyl bromide. Yield: 15%. M.p. 196-197_C. Compound 34.
Endo-3- (3- [2-cyanoethylthio] -1,2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1] heptane, oxalate and 3-bromopro- pionitrile. Yield: 42%. M.p. 168-169_C. Compound 35.
Endo-3- (3- [2, 4-difluorobenzylthio] -1,2, 5-thiadiazol-4- yloxy) -1-azabicyclo [2.2. l]heptane, oxalate from endo-3- (3-propylsulfonyl-l,2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 2, 4-difluorobenzyl bromide. Yield: 67%. M.p. 98-100_C. Compound 36.
Endo-3- (3- [2-fluoroethyl-1-thio]-1,2, 5-thiadiazol-4- yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-butylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. l]heptane, oxalate (example 8) and 1- bromo-2-fluoroethane. Yield: 59%. M.p. 131-133_C. Compound 37. EXAMPLE 1 0
The following compound was made in the same manner as described in example 5 by using the reagents indicated.
Endo-3- (3-butylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. l]heptane, oxalate from endo-3-(3- butylthio-1, 2, 5-thiadiazol-4-yloxy) -1-azabi¬ cyclo [2.2.1]heptane, oxalate. Compound 38.
EXAMPLE 11
Endo-3- (3- [3- (3-thienyl) -2-propyn-l-yloxy] -1,2, 5-thiadiazol-4- yloxy) -1-azabicyclo [2.2.1]heptane, oxalate
a) To a suspension of bis (triphenylphosphine) -palladium (II) chloride (300 mg, 0.42 mmol) and copper (I) iodide (100 mg, 0.50 mmol) in diisopropylamine (100 ml) under nitrogen was added 3-bromothiophene (4.9 g, 30 mmol) . After reflux under nitrogen for 1.5 h a solution of propargyl alcohol (3.0 g, 33 mmol) in diisopropylamine (50 ml) was added. After reflux for 5 h the reaction mixture was cooled, filtered and concentrated i_n vacuo . The residue was submitted to flash chromatography using ether/petroleum ether (1:1) as eluent to give 2 g (48%) of 3- (3-thienyl) -2-propyn-l-ol as a crude product.
b) A solution of 3- (3-thienyl) -2-propyn-l-ol (276 mg, 2.0 mmol) and sodium hydride (80%) (90 mg, 3.0 mmol) in dry
THF (10 ml) was stirred at room temperature for 1 h under nitrogen. A solution of endo-3- (3-butylsulfonyl-l, 2, 5- thiadiazol-4-yloxy) -1-azabicyclo [2.2.1 ] heptane (317 mg, 1.0 mmol) in dry THF (5 ml) was added. After 16 h the reaction was quenched with water and THF evaporated off. The product was extracted with ether (3 x) . The extracts were dried (MgSθ4), filtered and the solvent evaporated.
The product was taken up in acetone and precipitated with oxalic acid in acetone to give 123 mg (30%) of the title compound. M.p. 133-136_C. Compound 39.
EXAMPLE 12
Endo-3- (3- [3- (2-thienyl) -2-propyn-l-yloxy] -1, 2, 5- thiadiazol-4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate
a) To a suspension of tetrakis
(triphenylphosphine)palladium (300 mg, 0.25 mmol) and copper (I) iodide (100 mg, 0.50 mmol) in diisopropylamine (100 ml) under nitrogen was added 2-iodothiophene (6.3 g, 30 mmol) . After stirring 1.5 h at room temperature a solution of propargyl alcohol (3.0 g, 33 mmol) in diisopropylamine (50 ml) was added. After 16 h at room temperature the mixture was filtered and concentrated iji vacuo. The residue was submitted to flash chromatography using dichloromethane as eluent to give 3.0 g (73%) of 3- (2-thienyl) -2-propyn-l-ol as a crude product.
b) A solution of 3- (2-thienyl) -2-propyn-l-ol (276 mg, 2.0 mmol) and sodium hydride (80%) (90 mg, 3.0 mmol) in dry
THF (10 ml) was stirred at room temperature for 1 h under nitrogen. A solution of endo-3- (3-butylsulfonyl-l,2, 5- thiadiazol-4-yloxy) -1-azabicyclo [2.2. l]heptane (317 mg, 1.0 mmol) in dry THF (5 ml) was added. After stirring for 16 h the reaction was quenched with water and THF evapo¬ rated off. The product was extracted with ether. The product was precipitated as a HCl salt to give 253 mg (70%) of the title compound. M.p. 180-184 C. Compound 40. EXAMPLE 13
Endo-3- (3- [1-cyclopropylethyl-l-oxy] -1,2, 5-thiadiazol-4- yloxy) -1-azabicyclo [2.2.1] heptane, oxalate
A suspension of sodium hydride (50 mg, 1.5 mmol) in dry THF (5 ml) and a-methylcyclopropanemethanol (100 μl, 1.0 mmol) was stirred at room temperature for 1 h. The reaction was then added endo-3-butylsulfonyl-l, 2, 5- thiadiazol-4-yloxy) -1-azabicyclo[2.2. l]heptane (160 mg, 0.5 mmol) . After 16 h the reaction was quenched with ice- water, added potassium carbonate and the product extracted with dichloromethane (3 x) . The extracts were dried (MgSθ4) and the solvent evaporated. The product was taken up in acetone and precipitated with oxalic acid in acetone followed by ether to give 145 mg (50%) of the title compound. M.p. 134-137_C. Compound 41. Endo-3- (3- [3-phenyl-2-propynyl-l-oxy] -1,2, 5-thiadiazol-4- yloxy) -1-azabicyclo[2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1-azabi¬ cyclo[2.2.1]heptane, oxalate and 3-phenyl-2-propyn-l-ol . Yield: 81%. M.p. 158-159_C. Compound 5.
Endo-3- (3- [3- (3-methoxyphenyl) -2-propynyl-l-oxy] -1,2,5- thiadiazol-4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2. l]heptane, oxalate and 3- (3- methoxyphenyl) -2-propyn-l-ol. Yield: 47%. M.p. 142-143_C. Compound 6.
Endo-3- (3- [3-methyl-2-butenyl-l-oxy] -1, 2, 5-thiadiazol-4- yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. l]heptane, oxalate and 3-methyl-2-buten-l- ol. Yield: 55%. M.p. 112-115_C. Compound 7. Endo-3- (3- [2-cyclopropylethyl-l-oxy] -1,2, 5-thiadiazol-4- yloxy) -1-azabicyclo[2.2. l]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and cyclopropylethanol Yield: 74%. M.p. 132-133_C. Compound 8.
Endo-3- (3- [4-fluorobenzyloxy]-1,2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 4-fluorobenzyl alcohol. Yield: 62% M.p. 144-145_C. Compound 9.
Endo-3- (3- [2-butenyl-l-oxy] -1,2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and crotyl alcohol. Yield: 67%. M.p. 129-131_C. Compound 10.
Endo-3- (3- [2-butynyl-l-oxy] -1,2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 2-butyn-l-ol . Yield: 73%. M.p. 194-196_C. Compound 11.
Endo-3- (3-methylthioethoxy-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo- [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 2-hydroxyethylme- thyl sulfide. Yield: 60%. M.p. 117-119_C. Compound 12.
Endo-3- (3- [3-methyl-2-butenyl-l-oxy] -1, 2, 5-thiadiazol- 4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo- 3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 3-methyl-2-buten- l-ol. Yield: 55%. M.p. 112-115_C. Compound 7.
Endo-3- (3- [2-cyclopropylethyl-l-oxy] -1,2, 5-thiadiazol-4- yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and cyclopropylethanol. Yield: 74%. M.p. 132-133_C. Compound 8.
Endo-3- (3- [4-fluorobenzyloxy] -1,2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 4-fluorobenzyl alcohol. Yield: 62% M.p. 144-145_C. Compound 9.
Endo-3- (3- [2-butenyl-l-oxy] -1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. l]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and crotyl alcohol. Yield: 67%. M.p. 129-131_C. Compound 10.
Endo-3- (3- [2-butynyl-l-oxy]-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 2-butyn-l-ol . Yield: 73%. M.p. 194-196_C. Compound 11.
Endo-3- (3-methylthioethoxy-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo- [2.2. l]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 2-hydroxyethylme- thyl sulfide. Yield: 60%. M.p. 117-119_C. Compound 12. Endo-3- (3-methoxyethoxy-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 2-methoxyethanol. Yield: 78%. M.p. 139-141_C. Compound 13.
Endo-3- (3- [4-trifluoromethoxybenzyloxy] -1,2, 5-thiadiazol- 4-yloxy) -1-azabicyclo [2.2. l]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 4-
(trifluoromethoxy)benzyl alcohol. Yield: 77%. M.p. 116- 119 C. Compound 14. Endo-3- (3- [4, 4, 4-trifluorobutyl-l-oxy] -1,2, 5-thiadiazol- 4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. l]heptane, oxalate and 4,4,4- trifluorobutanol. Yield: 73%. M.p. 135-137_C. Compound 15.
Endo-3- (3- [2-fluoro-4- (trifluoromethyl) -benzyloxy] -1,2,5- thiadiazol-4-yloxy) -1-azabicyclo[2.2. l]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2.1]heptane, oxalate and 2-fluoro-4- (trifluoromethyl)benzyl alcohol. Yield: 73%. M.p. 112- 114_C. Compound 16. Endo-3- (3- [1- (3-methoxyphenyl) -4-methyl-l-pentyn-3- yloxy] -1,2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.l]heptane, oxalate from endo-3- (3- butylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and 1- (3- methoxyphenyl) -4-methyl-l-pentyn-3-ol. Yield: 35%. M.p. 144-147_C. Compound 20.
Endo-3- (3-cyclobutylmethyloxy-l, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2. l]heptane, oxalate from endo-3- (3- butylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and cyclobutyl methanol. Yield: 46%. M.p. 96-99_C. Compound 22. Endo-3- (3- [2,2,2-trifluoroethyl-1-oxy] -1, 2, 5-thiadiazol- 4-yloxy) -1-azabicyclo[2.2.1]heptane, oxalate from endo-3- (3-butylsulfonyl-l,2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. l]heptane, oxalate and 2,2,2- trifluoroethanol. Yield: 54%. M.p. 153-156_C. Compound
21.
Endo- (Z) -3- (3- (5- (4-fluorophenyl) -3-methyl-2-penten-4- yn-1-yloxy) -1,2, 5-thiadiazol-4-yloxy) -1- azabicyclo[2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. l]heptane, oxalate and (Z)-5-(4- fluorophenyl) -3-methyl-2-penten-4-yn-l-ol . M.p. 174- 177_C. Compound 24.
Endo-3- (3- [4- (3-methoxyphenyl) -3-butyn-2-yloxy] -1,2,5- thiadiazol-4-yloxy) -1-azabicyclo [2.2.1] heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2.1]heptane, oxalate and 4- (3- methoxyphenyl) -3-butyn-2-ol. Yield: 62%. M.p. 102-103_C. Compound 17.
Endo-3- (3- (2,2, 3, 3, 4, 4, 4-heptafluorobutyl-1-oxy) -1, 2, 5- thiadiazol-4-yloxy) -1-azabicyclo [2.2. l]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo [2.2.1] heptane, oxalate and 2,2,3,3,4,4,4- heptafluorobutan-1-ol. M.p.128-131_C. Compound 30. Endo-3- (3- (3- (3-furyl) -2-propyn-l-yloxy) -1,2,5- thiadiazol-4-yloxy) -1-azabicyclo[2.2.1]heptane, oxalate from endo-3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) - 1-azabicyclo[2.2.1]heptane, oxalate and 3- (3-furyl) -2- propyn-1-ol. M.p. 146-148_C. Compound 29.
Endo-3- (3- (2-pyridyl) -2-propyn-l-yloxy) -1,2,5- thiadiazol-4-yloxy) -1-azabicyclo[2.2.1]heptane, dioxalate from endo-3- (3-propylsulfonyl-l, 2, 5- thiadiazo1-4-yloxy) -1-azabicyclo [2.2.1]heptane, oxalate and (2-pyridyl) -2-propyn-l-ol . M.p. 158-160_C. Compound 28.
Endo-3- (3- (3-pyridyl) -2-propyn-l-yloxy) -1, 2, 5-thiadiazol- 4-yloxy) -1-azabicyclo [2.2.1]heptane, dioxalate from endo- 3- (3-propylsulfonyl-l, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and (3-pyridyl) -2- propyn-1-ol. M.p. 136-139 C. Compound 26.
Endo- (E) -3- (3- (5- (4-fluorophenyl) -3-methyl-2-penten-4-yn- 1-yloxy) -1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3-(3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate and (E)-5-(4- fluorophenyl) -3-methyl-2-penten-4-yn-l-yloxy) . M.p. 82- 84_C. Compound 25.
Endo- (E/Z) -3- (3- (5- (4-fluorophenyl) -2-penten-4-yn-l- yloxy) -1,2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, oxalate from endo-3- (3- propylsulfonyl-1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. l]heptane, oxalate and 5- (4-fluorophenyl) - 2-penten-4-yn-l-ol. M.p. 185-188_C. Compound 27.

Claims

We Claim :
1 . A compound of formula I :
Figure imgf000056_0001
W is S or 0;
R8 is selected from the group consisting of hydrogen and C1-C4 alkyl;
R10' is C2-C5 alkynyl; R11' is aryl or 5 to 6 member heterocyclic ring each of which is optionally substituted with one or more independently selected from the group consisting of halogen, -CN, Cι-4-alkyl, Cι-4-alkoxy, -OCF3, -CF3, -CONH2,
-CSNH2; -OH, -COR6', CH2-OH, and -NH2; G is selected from one of the following azacyclic or azabicyclic ring systems:
Figure imgf000057_0001
or G is optionally substituted C3-C8 cycloalkyl wherein the cycloalkyl substituents are selected from R1 and R2; or optionally substituted Cι-6-alkyl wherein the substitution is -NR6R7;
R6 and R7 independently are selected from the group consisting of hydrogen and Cι-6-alkyl; or R6 and R7 together with the nitrogen atom optionally form a 4- to 6-member ring;
R1 and R2 independently are selected from the group consisting of hydrogen, Cι-15-alkyl, C2-5~alkenyl, C2-5- alkynyl, Cι-ιo~alkoxy, and Cι-5-alkyl substituted with one or more independently selected from the group consisting of -OH, -COR6', CH2-OH, halogen, -NH2, carboxy,
Figure imgf000057_0002
and phenyl;
R9 and R9' are each independently selected from the group consisting of hydrogen, halogen, Cι-4-alkoxy, Cι-4-alkyl, -CN, -OCF3, -CONH2 and -CSNH2; R6' is hydrogen, Cι-6-alkyl;
R3 is selected from the group consisting of hydrogen, Ci- 5-alkyl, C2-5-alkenyl and C2-5-alkynyl; n is 0, 1 or 2; m is 0, 1 or 2; p is 0, 1 or 2; q is 1 or 2; r is 0, 1 or 2; is a single or double bond; and pharmaceutically acceptable salts and solvates thereof.
2. A compound of Claim 1 wherein R10' is propargyl.
3. A compound of Claim 2 wherein R11' is aryl.
4. A compound of Claim 1 wherein G is azabicyclo 2.2.1 heptane.
5. A compound of Claim 3 wherein R8 is hydrogen.
6. A compound of Claim 5 wherein W is 0.
7. A compound of Claim 3 wherein G is azabicyclo [2.2.1] heptane.
8. A compound of Claim 7 wherein R8 is ethyl.
9. A compound of Claim 7 wherein R8 is propyl.
10. A compound of Claim 1 selected from the group consisting of Endo-3- (3- (3, 3, 3- trifluoropropylthio) -1,2, 5-thiadiazol-4-yloxy) -1-azabi¬ cyclo[2.2.1]heptane, oxalate, Endo-3- (3- (4,4,4- trifluorobutylthio) -1,2, 5-thiadiazol-4-yloxy) -1-azabic¬ yclo [2.2.1]heptane, Endo-3- (3- [4-cyanobenzylthio] -1,2,5- thiadiazol-4-yloxy) -1-azabicyclo [2.2.1]heptane, Endo-3- (3- [2-cyanoethylthio] -1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2. l]heptane, Endo-3- (3- [2, 4- difluorobenzylthio] -1,2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, Endo-3- (3- [2-fluoroethyl-1- thio] -1,2, 5-thiadiazol-4-yloxy) -1-azabicyclo- [2.2.1]heptane, Endo-3- (3-butylsulfonyl-l, 2, 5-thiadiazol- 4-yloxy) -1-azabicyclo [2.2.l]heptane, Endo-3- (3- [3- (3- thienyl) -2-propyn-l-yloxy] -1, 2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane, and Endo-3- (3- [3- (2-thienyl) -2- propyn-1-yloxy] -1,2, 5-thiadiazol-4-yloxy) -1- azabicyclo [2.2.1]heptane.
11. A compound of Claim 1, as described by any one of the examples herein.
12. A formulation comprising a compound of Claim 1 and one or more excipients, diluents, and/or carriers therefor.
13. A method for treating a condition which is mediated by a muscarinic receptor, comprising administering an effective amount of a compound of Claim 1 to a patient in need thereof.
14. A method of Claim 13 wherein the condition is selected from the group consisting of Alzheimer's disease, severely painful conditions, glaucoma, psychosis, anxiety, mania, bipolar disorder, schizophrenia or schizophreniform conditions, depression, sleeping disorders, epilepsy, cerebral ischemia, and gastrointestinal motility disorders.
15. A method of Claim 14 wherein the condition is Alzheimer's disease.
16. A method of Claim 14 wherein the condition is a psychosis.
17. A compound of formula II
Figure imgf000060_0001
wherein R is selected from the group consisting of -OR4, -SR4, -SOR4, -S02R4, -Z-C3-10-cycloalkyl, -Z-C4-12- (cycloalkylalkyl) which is optionally substituted with straight or branched Cι-6_alkyl or R is selected from the group consisting of -OR5Y, -SR5Y, -0R5ZY, -SR5ZY, - OR5ZR4, and -SR5ZR4;
R4 is selected from the group consisting of straight or branched Ci-15-alkyl, straight or branched C2-l5~alkenyl, straight or branched C2-15_alkynyl and straight or branched C4-i5-alkenynyl, each of which is optionally substituted with one or more independently selected from the group consisting of halogen (s), -CF3, -CN, Y and phenyl which is optionally substituted with one or more independently selected from the group consisting of -OH, halogen, -CN, straight or branched Cι-4-alkyl, straight or branched
Ci-4-alkylthio, straight or branched Cι-4-alkoxy, -SCF3, -OCF3, -CONH2, -CSNH2, and CF3;
Z is oxygen or sulphur;
R5 is straight or branched Cι-15-alkylene, straight or branched C2-l5~alkenylene, straight or branched C2-15- alkynylene or straight or branched C4-i5-alkenynylene; Y is a 5 or 6 membered heterocyclic group optionally substituted with one or more independently selected from the group consisting of -OH, halogen, -Nθ2, -CN, straight or branched Ci-4-alkyl, straight or branched C1-4- alkylthio, straight or branched Cι-4-alkoxy, -SCF3, - OCF3, -CF3, -CONH2 and -CSNH2; or a pharmaceutically acceptable salt or solvate thereof.
18. A compound of claim 17 wherein R is selected from the group consisting of -OR4 or -SR4, wherein R4 is as defined above.
19. A compound of Claim 18 wherein R4 is selected from the group consisting of straight or branched C1-15- alkyl, straight or branched C2-15-alkenyl, straight or branched C2-15~alkynyl and straight or branched C4-15- alkenynyl, each of which is substituted; with one or more independently selected from the group consisting of halogen(s), -CF3, -CN, Y and phenyl which is optionally substituted with one or more independently selected from the group consisting of -OH, halogen, -CN, straight or branched Cι-4-alkyl, straight or branched Cι-4-alkylthio, straight or branched Cι-4-alkoxy, -SCF3, -OCF3, -CONH2, - CSNH2, and CF3, and Y is as defined above.
20. A compound of Claim 19 wherein R4 is propynyl which is optionally substituted with straight or branched C2-4~alkyl and which is substituted with phenyl or Y each of which is optionally substituted with one or more independently selected from the group consisting of -OH, halogen, -NO2, -CN, straight or branched
Ci-4-alkyl, straight or branched Cι-4-alkylthio, straight or branched Cι-4-alkoxy, -SCF3, -OCF3, -CF3, -CONH2 and -
CSNH2.
21. A compound as claimed in Claim 1 for use in the manufacture of a medicament.
PCT/US1997/006679 1996-04-23 1997-04-23 Heterocyclic compounds WO1997040042A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP9538263A JP2000509044A (en) 1996-04-23 1997-04-23 Heterocyclic compounds
US09/171,793 US6069159A (en) 1996-05-10 1997-04-23 Heterocyclic compounds
AU26794/97A AU2679497A (en) 1996-04-23 1997-04-23 Heterocyclic compounds
EP97918771A EP0900217A4 (en) 1996-04-23 1997-04-23 Heterocyclic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1600996P 1996-04-23 1996-04-23
US60/016,009 1996-04-23

Publications (1)

Publication Number Publication Date
WO1997040042A1 true WO1997040042A1 (en) 1997-10-30

Family

ID=21774860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/006679 WO1997040042A1 (en) 1996-04-23 1997-04-23 Heterocyclic compounds

Country Status (5)

Country Link
EP (1) EP0900217A4 (en)
JP (1) JP2000509044A (en)
AU (1) AU2679497A (en)
CA (1) CA2251974A1 (en)
WO (1) WO1997040042A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426355B1 (en) 1998-12-09 2002-07-30 American Home Products Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646289A (en) * 1994-10-24 1997-07-08 Eli Lilly And Company Heterocyclic compounds and their preparation and use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK198390D0 (en) * 1990-08-21 1990-08-21 Novo Nordisk As HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE
DK198590D0 (en) * 1990-08-21 1990-08-21 Novo Nordisk As HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE
WO1993014089A1 (en) * 1992-01-13 1993-07-22 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
WO1994018201A1 (en) * 1993-02-12 1994-08-18 Sankyo Company, Limited Isoxazoleoxy derivative
ES2111197T3 (en) * 1993-04-21 1998-03-01 Tosoh Corp 3,4-DIOXI-1,2,5-TIADIAZOLES IN PART USEFUL AS FUNGICIDES.
JPH07188017A (en) * 1993-09-30 1995-07-25 Souyaku Gijutsu Kenkyusho:Kk Antiviral agent containing thiadiazole derivative

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646289A (en) * 1994-10-24 1997-07-08 Eli Lilly And Company Heterocyclic compounds and their preparation and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0900217A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426355B1 (en) 1998-12-09 2002-07-30 American Home Products Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group

Also Published As

Publication number Publication date
EP0900217A4 (en) 2001-05-23
EP0900217A1 (en) 1999-03-10
CA2251974A1 (en) 1997-10-30
AU2679497A (en) 1997-11-12
JP2000509044A (en) 2000-07-18

Similar Documents

Publication Publication Date Title
US5821371A (en) Heterocyclic compounds and their preparation and use
US6030966A (en) Heterocyclic compound and their use
US5852037A (en) Method for treating anxiety
US5834458A (en) Heterocyclic compounds and their use
US6117883A (en) Heterocyclic compounds
US6069159A (en) Heterocyclic compounds
EP0900217A1 (en) Heterocyclic compounds
US6187798B1 (en) Heterocyclic compounds
EP0776897A1 (en) Heterocyclic compounds and their use
US6720342B2 (en) Heterocyclic compounds and their preparation and use
US6124312A (en) Heterocyclic compounds
EP0891363B1 (en) Heterocyclic compounds and their preparation and use
EP0912183A1 (en) Heterocyclic compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2251974

Country of ref document: CA

Ref country code: CA

Ref document number: 2251974

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997918771

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997918771

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09171793

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1997918771

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载